

1 **Longitudinal Analysis Over Decades Reveals the Development and Immune Implications**
2 **of Type I Interferon Autoantibodies in an Aging Population**

3
4 Sonja Fernbach^{a,†}, Nina K. Mair^{a,†}, Irene A. Abela^{a,b}, Kevin Groen^a, Roger Kuratli^a, Marie Lork^a,
5 Christian W. Thorball^c, Enos Bernasconi^d, Paraskevas Filippidis^e, Karoline Leuzinger^f, Julia
6 Notter^g, Andri Rauch^h, Hans H. Hirschⁱ, Michael Huber^a, Huldrych F. Günthard^{a,b}, Jacques
7 Fellay^{c,j}, Roger D. Kouyos^{a,b}, Benjamin G. Hale^{a,*}, and The Swiss HIV Cohort Study

8
9 ^aInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.

10 ^bDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
11 University of Zurich, Zurich, Switzerland.

12 ^cPrecision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne,
13 Switzerland.

14 ^dDivision of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and
15 University of Southern Switzerland, Lugano, Switzerland.

16 ^eInfectious Diseases Service, Department of Medicine, Lausanne University Hospital and
17 University of Lausanne, Lausanne, Switzerland.

18 ^fClinical Virology, University Hospital Basel, Basel, Switzerland.

19 ^gDivision of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

20 ^hDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern,
21 Bern, Switzerland.

22 ⁱTransplantation and Clinical Virology, Department of Biomedicine, University of Basel, Basel,
23 Switzerland.

24 ^jSchool of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

25
26 [†]These authors contributed equally to this work and are listed alphabetically.

27

28 *Corresponding author: hale.ben@virology.uzh.ch; 0000-0002-3891-9480 (ORCID).

29

30 Running title: Development and consequences of IFN-I autoAbs

31 Character count: 38,057 (not including spaces, figure legends, methods, or references)

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77

ABSTRACT

Pre-existing autoantibodies (autoAbs) neutralizing type I interferons (IFN-I: IFN α , IFN β , IFN ω) have recently been described as significant contributors to the severity of viral infectious diseases. Here, we explore the development and consequences of anti-IFN-I autoAbs at high-resolution using retrospective samples and data from 1876 well-treated individuals >65 years of age enrolled in the Swiss HIV Cohort Study, a nationwide, longitudinal cohort with up to 35 years of follow-up. Approximately 1.9% of individuals developed anti-IFN-I autoAbs, with a median onset age of ~63 years (range 45-80). Once developed, anti-IFN-I autoAbs persisted for life, and generally increased in titer over years. Most individuals developed distinct neutralizing and non-neutralizing anti-IFN-I autoAb repertoires at discrete times that selectively targeted various combinations of IFN α , IFN β , and IFN ω . Longitudinal analyses further revealed that emergence of neutralizing anti-IFN α autoAbs correlated with reduced IFN-stimulated gene (ISG) levels, indicating impairment of innate immunity. Patient data review suggested that prior recorded viral infections and autoimmune history influence the likelihood of mounting anti-IFN-I autoAbs. Indeed, systematic measurements in biobanked samples revealed significant enrichment of pre-existing autoreactivity against clinically relevant autoantigens in individuals who later developed anti-IFN-I autoAbs. In this context, we describe lifelong neutralizing anti-IFN α autoAbs (and impaired innate immunity), that manifested in an individual following IFN α therapy, and who was retrospectively found to have had pre-existing autoreactivity to β 2-glycoprotein-I before IFN α treatment. Our decades-spanning longitudinal analyses illuminate the development and immune implications of anti-IFN-I autoAbs in an aging population, and support a ‘two-hit’ hypothesis whereby loss of self-tolerance prior to immune-triggering with endogenous or exogenous IFN-I may pose a risk for developing late-onset, lifelong IFN-I functional deficiency.

78

INTRODUCTION

79

80 Deficiencies in the human type I interferon (IFN-I) system leave individuals susceptible to a
81 range of severe viral diseases typically caused by pathogens to which they lack pre-existing
82 humoral immunity (reviewed in (Duncan et al., 2021; Meyts and Casanova, 2021; Stertz and
83 Hale, 2021)). While life-threatening viral diseases linked directly to genetic defects in the IFN-I
84 system are extremely rare (and mainly manifest themselves in the very young) (Duncan et al.,
85 2021), it has recently become apparent from cross-sectional studies that a functional defect
86 caused by autoantibodies (autoAbs) targeting IFN-I cytokines is not particularly rare in elderly
87 populations (reviewed in (Bastard et al., 2024a; Hale, 2023)). Specifically, the prevalence of
88 autoAbs neutralizing the IFN-I cytokines IFN α and/or IFN ω increases sharply with age in
89 otherwise healthy individuals, such that a conservative estimate of prevalence in those >70
90 years old is about eight times higher (1.4%) than that in younger individuals (0.17%) (Bastard et
91 al., 2021). Furthermore, the presence of neutralizing anti-IFN-I autoAbs in individuals has been
92 associated with an increased susceptibility to severe infections caused by several viral
93 pathogens, including SARS-CoV-2 (Akbil et al., 2022; Bastard et al., 2024b; Bastard et al., 2020;
94 Busnadiago et al., 2022; Chauvineau-Grenier et al., 2022; Credle et al., 2022; Eto et al., 2022;
95 Frasca et al., 2022; Goncalves et al., 2021; Manry et al., 2022; Mathian et al., 2022; Scordio et
96 al., 2022; Solanich et al., 2021; Troya et al., 2021; Wang et al., 2021), MERS-CoV (Alotaibi et
97 al., 2023), influenza A virus (Zhang et al., 2022), West Nile virus (Gervais et al., 2023; Lin et al.,
98 2023), and various herpesviruses (Bayat et al., 2015; Burbelo et al., 2010; Busnadiago et al.,
99 2022; Hetemaki et al., 2021; Mathian et al., 2022; Mogensen et al., 1981; Pozzetto et al., 1984).
100 Given that more than 100 million people worldwide have been estimated to potentially harbor
101 neutralizing anti-IFN-I autoAbs (Bastard et al., 2024a), and are therefore at increased risk of
102 severe infectious disease outcomes, it is critical to understand factors associated with their
103 development and pathogenic mechanisms in order to inform future mitigation strategies.

104
105 Multiple distinct host genetic defects converging on disruption of central T-cell tolerance in the
106 thymus have been shown to underlie the development of anti-IFN-I autoAbs in several patient
107 cohorts (reviewed in (Bastard et al., 2024a; Hale, 2023)). The best characterized examples of
108 these defects include mutations in the *AIRE* gene, which encodes an autoimmune regulator that
109 normally ensures negative selection of autoreactive T-cells (Meager et al., 2006; Meyer et al.,
110 2016), and mutations in the *NFKB2*, *MAP3K14* (NIK) and *RELB* genes, that encode components
111 of the alternative NF- κ B pathway and regulate *AIRE* expression (Bodansky et al., 2022; Le
112 Voyer et al., 2023; Ramakrishnan et al., 2018; Sjogren et al., 2022). Patients with these genetic
113 defects exhibit thymic abnormalities and reduced self-tolerance, and typically develop anti-IFN-I
114 autoAbs in early childhood (Le Voyer et al., 2023; Meager et al., 2006), which has been
115 speculated to occur following an infection event triggering ‘immunization’ with endogenous IFN-I
116 (Hale, 2023). However, the role of genetics and other pre-disposing factors in contributing to the
117 increased prevalence of anti-IFN-I autoAbs in elderly populations is little understood, and it still
118 remains to be resolved at the individual level at what point in life these autoAbs develop, their
119 longevity, and their impact on an individual’s innate antiviral defenses. Furthermore, associations
120 between potential ‘immunization’ events, such as infections, and the development of anti-IFN-I
121 autoAbs have yet to be investigated. These gaps in our knowledge mainly result from a lack of
122 available longitudinal samples and lack of systematic clinical histories taken from before anti-
123 IFN-I autoAbs developed in individuals, as well as the limited time that has passed so far for
124 patients recently identified to harbor anti-IFN-I autoAbs, which has prevented long-term follow-up
125 studies.

126
127 Here, we sought to leverage the Swiss HIV Cohort Study (SHCS) as a large nationwide,
128 systematic, longitudinal infectious disease cohort to study the development and consequences
129 of anti-IFN-I autoAbs in elderly individuals. The SHCS was founded in 1988, and contains

130 historic, semiannually biobanked plasma and cell samples, as well as clinical data, from more
131 than 21,000 people living with HIV (PLH) over the course of 35 years (Scherrer et al., 2022).
132 With improved success of long-term antiretroviral therapy, life-expectancy in this cohort is now
133 approaching that of the general population in Switzerland (Gueler et al., 2017). Thus, this well-
134 treated cohort is aging, and individuals >50 years of age make up around 60% of the currently
135 enrolled patients, with most having been followed-up for almost half their adult lives.
136 Furthermore, IFN-I therapy was widely used in this cohort for hepatitis C virus (HCV) treatment
137 before directly acting antivirals became available (Baumann et al., 2024). Using this resource,
138 we wanted to track the levels of neutralizing and non-neutralizing anti-IFN-I autoAb repertoires
139 (targeting IFN α , IFN β , and IFN ω) in individuals over decades at high-resolution, thus providing
140 key information on the timing of autoAb induction and their longevity. Furthermore, we aimed to
141 describe the impact of neutralizing anti-IFN-I autoAbs on innate antiviral defenses, and to
142 perform exploratory analyses of clinical record data to investigate whether pre-disposing factors
143 or events influence the likelihood of anti-IFN-I autoAb development.

144

145

RESULTS

146

147 **Identification and characterization of anti-IFN-I autoAbs in an aging, longitudinally-** 148 **sampled, infectious disease patient cohort.**

149 To systematically investigate the age-related development of anti-IFN-I autoAbs in the SHCS,
150 we initially selected recent plasma samples taken from a sub-cohort of 1876 well-treated
151 individuals >65 years of age (82% male, median year of birth 1949, IQR 1943-1954;
152 **Supplementary Table 1**). Age and sample availability were the only criteria considered in this
153 selection. We then applied a multiplexed bead-based assay to screen these samples for IgG
154 autoAbs binding to the representative type I IFNs: IFN α 2, IFN β and IFN ω . Samples identified to
155 be positive were subsequently tested for neutralization capacity against the respective IFN-I at

156 different doses. We observed that 0.85% of individuals (16/1876) had neutralizing autoAbs
157 against IFN α 2, 0.32% of individuals (6/1876) had neutralizing autoAbs against IFN β , and 0.48%
158 of individuals (9/1876) had neutralizing autoAbs against IFN ω (**Fig. 1A**). Overall, 1.17% of the
159 individuals in our >65 cohort (22/1876) had neutralizing autoAbs against at least one IFN-I, a
160 prevalence similar to that noted previously in similarly-aged, otherwise healthy, individuals
161 (Bastard et al., 2021). An additional 0.69% of individuals in our >65 sub-cohort (13/1876) had
162 detectable anti-IFN-I autoAbs that were non-neutralizing (0.11% IFN α 2, 0.21% IFN β and 0.48%
163 IFN ω). With regards patient ethnicity, most likely source of HIV-1 infection, and baseline levels
164 of HIV-1 RNA, there were no clear differences between those with detectable levels of anti-IFN-I
165 autoAbs compared to those without (**Supplementary Table 1**). However, males made up 94.3%
166 (33/35) of those identified to have anti-IFN-I autoAbs as compared to 81.9% (1507/1841) of
167 males in the population without anti-IFN-I autoAbs, suggesting a trend towards increased
168 prevalence in males (**Supplementary Table 1**). Notably, one individual (P5) had IgG autoAbs
169 binding and neutralizing all three type I IFNs, while most had binding autoAbs specific for IFN α 2
170 (0.53%, 10/1876), IFN ω (0.43%, 8/1876), or both IFN α 2 and IFN ω (0.37%, 7/1876) (**Figs. 1B &**
171 **1C**). Seven individuals (0.37%) only had IgG autoAbs specific to IFN β , while two individuals
172 (0.11%) had IgG autoAbs against IFN β and IFN ω (**Figs. 1B & 1C**). While most anti-IFN-I
173 autoAb-positive plasmas neutralized the respective IFN-I, it was striking that the majority of
174 plasmas positive for anti-IFN ω autoAbs alone appeared to be non-neutralizing at the plasma
175 dilution tested (**Fig. 1C**). Further characterization of each individual's anti-IFN-I IgG autoAb
176 subclasses revealed a binding antibody response dominated by IgG1 autoAbs in most
177 individuals (**Figs. 1D & 1E**). However, it was interesting to observe that IgG4 was also a
178 commonly identified subclass of anti-IFN α 2 and anti-IFN ω IgG autoAbs (statistically significant
179 for IFN α 2, but not for IFN ω), and that IgG4 even dominated in a few individuals with these types
180 of autoAbs. In contrast, it was notable that anti-IFN β IgG4 did not dominate in any individual
181 (**Fig. 1E**). Anti-IFN-I IgG autoAbs of the IgG3 subclass were also sporadically detected, and

182 represented the main IgG autoAb in some individual patients, while anti-IFN-I IgG2 autoAbs
183 were very rarely detected or of low titer (**Figs. 1D & 1E**). Thus, the anti-IFN-I IgG autoAb
184 landscape in our sub-cohort is mostly comprised of the IgG1 subclass. Overall, our screening
185 data reveal the diversity of anti-IFN-I autoAbs in a sub-cohort of PLH individuals >65 years of
186 age, and indicate that the prevalence of these autoAbs in this sub-cohort (1.17% for neutralizing
187 autoAbs only) is highly comparable to that previously reported in a similarly-aged healthy cohort
188 (Bastard et al., 2021).

189
190 **High-resolution longitudinal analysis of anti-IFN-I autoAb levels reveals their acute age-**
191 **associated development and persistence over decades.**

192 For all 35 anti-IFN-I autoAb positive individuals, as well as for 35 anti-IFN-I autoAb negative
193 individuals (matched for sex and year of birth), we obtained historic biobanked plasma samples
194 from all timepoints available in the SHCS since enrollment. Samples were typically available
195 from two timepoints (approximately 6-monthly) per year, and spanned an average of 20.2 years
196 (range 9-27) for each anti-IFN-I autoAb positive individual. As an example, the anti-IFN-I autoAb
197 positive individual with the most samples available had 52 plasma samples that were taken
198 between the ages of 43 and 70 (i.e. over a 27-year period). For all longitudinal plasma samples
199 we assessed levels of IgG autoAbs binding to each type I IFN, and subsequently tested most
200 samples for IFN-I neutralization capacity, resulting in a temporal overview of anti-IFN-I autoAb
201 binding and neutralization development for each individual (**Fig. 2 and Supplementary Fig. 1**).
202 Despite individual heterogeneity with regard to anti-IFN-I autoAb reactivity, several common
203 features were apparent from analyzing the anti-IFN-I autoAb positive population. Firstly, for
204 34/35 anti-IFN-I autoAb positive individuals, anti-IFN-I autoAbs were undetectable for many
205 years in the available samples prior to the occurrence of a positive sample, indicating that the
206 autoAbs did not exist in these individuals for most of their lives. This is in stark contrast with
207 patients harboring mutations in the *AIRE* gene or in genes of the alternative NF- κ B pathway,

208 where anti-IFN-I autoAbs are detectable very early in childhood (Le Voyer et al., 2023; Meager
209 et al., 2006). Indeed, confirming the age-related onset of anti-IFN-I autoAbs in our study
210 population, the median ages of new-onset autoAb detection were remarkably similar, at 63, 63,
211 and 61.5 years for anti-IFN α 2, anti-IFN β , and anti-IFN ω , respectively, with a range of ages
212 spanning years 45-80 (**Fig. 2A**). Secondly, anti-IFN-I autoAbs first developed at a specific,
213 discrete timepoint in each individual, indicating that their induction was likely triggered by a
214 certain acute event. Thirdly, anti-IFN-I autoAbs generally increased in binding titers over time for
215 anti-IFN α 2 and anti-IFN ω , but not for anti-IFN β (**Fig. 2B**), which might reflect increases in
216 autoAb abundance or increases in avidity towards the IFN α 2 and anti-IFN ω antigens. However,
217 it is unclear why this appears to be antigen specific. Finally, with the exception of rare transient
218 'blips' at early timepoints (e.g. P8), it was apparent that the presence of anti-IFN-I autoAbs never
219 resolved, and once developed they persisted continuously in subsequent plasma samples (**Figs.**
220 **2C-I and Supplementary Fig. 1**). For example, the longest duration of neutralizing anti-IFN-I
221 autoAbs detected in our study sub-cohort was approximately 15 years (P12 and P32; **Fig. 2D**),
222 and 11 individuals maintained anti-IFN-I autoAbs for at least 10 years each. On the contrary,
223 anti-IFN-I binding autoAbs were never detected at any timepoint in the 35 negative individuals
224 tested longitudinally (see examples in **Fig. 2I and Supplementary Fig. 2**). Overall, our
225 longitudinal data reveal acute induction of anti-IFN-I autoAbs that can occur in some individuals
226 around the age of 60-65 years, which is followed by subsequent lifelong maintenance of these
227 anti-IFN-I autoAbs.

228

229 **Distinct individual variation in the timing and specificity of anti-IFN-I autoAb** 230 **development.**

231 We observed various phenotypes relating to anti-IFN-I autoAbs that were particular to certain
232 individuals, or to groups of individuals. For example, it was striking in the single individual with
233 autoAbs binding and neutralizing all three type I IFNs (P5) (**Fig. 2C**) that each anti-IFN-I autoAb

234 developed at different times over the course of seven years, with anti-IFN α 2 autoAbs developing
235 after age 55, anti-IFN β autoAbs developing after age 61, and anti-IFN ω autoAbs developing
236 after age 62. This suggests that different acute events might have triggered development of
237 these different neutralizing autoAb reactivities at different times. A similar pattern was observed
238 in individual P32, who developed neutralizing anti-IFN α 2 autoAbs after age 55, followed by
239 neutralizing anti-IFN ω autoAbs around age 60 (**Fig. 2D**). However, anti-IFN β autoAbs never
240 developed in P32, highlighting inter-individual variability in the types of IFN-I antigens to which
241 anti-IFN-I autoAbs can be raised. While reactivity to both IFN α 2 and IFN ω was not uncommon to
242 observe (7/35 individuals; **Figs. 2D** and **2G**) there were many examples where reactivity to
243 either only IFN α 2 (10/35 individuals; e.g. **Fig. 2F** and **Supplementary Fig. 1C**) or IFN ω (8/35
244 individuals; **Supplementary Figs. 1B** and **1E**) occurred, indicating that specificity of reactivity at
245 the individual level, even between these two closely related type I IFNs, is possible despite the
246 known potential for IFN α /IFN ω cross-reactive autoAbs to exist (Meyer et al., 2016). Furthermore,
247 such lack of reactivity to both IFN α 2 and IFN ω was not simply a consequence of short time
248 periods preventing the broadening of reactivity from one IFN to the other, as some individuals
249 had specific anti-IFN α 2 or anti-IFN ω autoAbs for 8 years (P4, P21; **Fig. 2F** and **Supplementary**
250 **Fig. 2C**), 11 years (P7), or even 15 years (P10; **Supplementary Fig. 2E**) without developing
251 autoAbs against the other IFN. In a similar specificity example, individual P6 developed anti-
252 IFN ω autoAbs after the age of 80 and then developed anti-IFN β autoAbs after the age of 82, but
253 never developed anti-IFN α 2 autoAbs (**Fig. 2E**). Thus, even within 35 individuals, almost all
254 combinations of anti-IFN-I autoAb reactivities could be observed, which also extended to
255 variations of whether the autoAbs were able to neutralize the action of IFN-I or not. Overall, our
256 longitudinal analyses reveal that neither time of induction, binding specificity, nor neutralization
257 capacity of anti-IFN-I autoAb repertoires can be generalized, but probably reflect distinct host or
258 environmental factors specific to each individual.

259

260 **Development of neutralizing anti-IFN α 2 autoAbs is associated with compromised**
261 **baseline IFN-stimulated gene levels.**

262 Our production of high-resolution longitudinal anti-IFN-I autoAb binding and neutralization data in
263 a highly-studied infectious disease cohort, combined with the availability of biobanked samples
264 and clinical data spanning multiple decades, gave us the possibility to dissect consequences of
265 anti-IFN-I autoAb development in individual patients. Given the heterogeneity of types of anti-
266 IFN-I autoAbs observed in our sub-cohort, we focused studies on individuals who developed
267 neutralizing anti-IFN α 2 autoAbs, with the rationale that this was the largest ‘homogeneous’ sub-
268 group (n=16), and that neutralization capacity was most likely to have explainable functional
269 consequences. We began by looking at the consequences of anti-IFN-I autoAb development on
270 well-documented database-recorded outcomes related to HIV-1 viral loads and consequences,
271 incidences of other viral infections (e.g. herpes zoster, HSV-1 and CMV), bacterial and fungal
272 infections, and outcomes such as diabetes or cancers. For each individual, we analyzed these
273 outcomes for their whole lifetime following first detection of neutralizing anti-IFN α 2 autoAbs, and
274 compared the results to anti-IFN-I autoAb negative individuals within the SHCS database who
275 were matched for sex, registration date, study center, and year of birth (n=62). We did not
276 observe a significant effect of neutralizing anti-IFN α 2 autoAbs on any of the recorded outcomes
277 (**Supplementary Table 2**) which, for HIV-1 at least, might reflect the high effectiveness of long-
278 term antiretroviral therapy. Furthermore, at the cellular level, we did not observe that
279 development of neutralizing anti-IFN α 2 autoAbs correlated with any changes to specific blood
280 cell compositions, including leukocytes, platelets, or various lymphocyte sub-populations (**Fig.**
281 **3A**). To investigate directly whether the development of neutralizing anti-IFN α 2 autoAbs had
282 consequences for IFN-stimulated gene (ISG) expression, we next analyzed baseline ISG levels
283 in multiple frozen biobanked PBMC samples that were available from 13 individuals who
284 developed neutralizing anti-IFN α 2 autoAbs, as well as from 13 age-matched negative-control
285 individuals who never developed anti-IFN-I autoAbs. For each autoAb-positive individual, we

286 obtained 2-3 PBMC samples from timepoints before, and 2-3 PBMC samples from timepoints
287 after, autoAb development. In the case of negative-control individuals, we obtained a similar
288 number of samples from age-matched timepoints. Without culturing, total RNA was extracted
289 directly from frozen PBMCs and subjected to RT-qPCR analysis for a panel of 8 well-known ISG
290 mRNAs: *MX1*, *RIGI*, *IRF9*, *RSAD2*, *IFITM3*, *IFIT2*, *IFIT3*, and *IFI44*. As shown in **Fig. 3B**, mRNA
291 levels of all ISGs were significantly reduced in autoAb-positive individuals subsequent to their
292 development of neutralizing anti-IFN α 2 autoAbs. In contrast, baseline ISG mRNA levels were
293 not reduced in autoAb-negative individuals at age-matched timepoints, and more than half of
294 these individuals actually exhibited increased levels of several ISGs over time (**Fig. 3C**). Overall,
295 these results build on previous cross-sectional descriptions of a correlation between neutralizing
296 anti-IFN α autoAbs and low ISG levels (Abers et al., 2021; Bastard et al., 2020; Kisand et al.,
297 2008; Koning et al., 2021; Lopez et al., 2021; van der Wijst et al., 2021; Wang et al., 2021), and
298 reveal that age-associated development of neutralizing anti-IFN α 2 autoAbs can have clear
299 temporal functional consequences, leading to compromised baseline ISG levels and thus
300 impaired innate antiviral responses.

301

302 **Prior virus infections may influence anti-IFN-I autoAb development.**

303 Beyond understanding the functional consequences of anti-IFN-I autoAbs, our longitudinal
304 dataset gave us the unique opportunity to probe the clinical records of each patient and to
305 understand factors potentially influencing the development of anti-IFN-I autoAbs. To do this, we
306 initially analyzed differences between our 35 anti-IFN-I autoAb positive patients and 138 autoAb
307 negative patients (matched for sex, registration date, study center, and year of birth) at all
308 timepoints that preceded first onset of anti-IFN-I autoAbs in positive individuals. Given the
309 matching for registration date and year of birth, the same timepoints could be considered for the
310 negative individuals. Out of 30 parameters investigated in an exploratory study, which were
311 either chosen due to their routine recording in the SHCS database or their infection-relatedness,

312 only prior CMV seropositivity and prior diagnosis of herpes zoster showed significant differences
313 between the two groups (**Supplementary Table 3** and **Figs. 4A-B**). Notably, prior CMV
314 seropositivity had a small negative association with anti-IFN-I autoAb development ($p=0.00696$;
315 **Fig. 4A**), suggesting a potential protective effect of CMV infection on anti-IFN-I autoAb
316 development. Indeed, CMV seropositivity has previously been reported to also negatively
317 associate with the development of multiple sclerosis (Sundqvist et al., 2014; Waubant et al.,
318 2011), an autoimmune disease where heterogeneous pathogenic autoAbs may play important
319 roles (Höftberger et al., 2022). Thus, it could be that CMV persistence contributes to subtle
320 immunomodulatory changes to the host that reduce certain autoimmune responses in some
321 otherwise predisposed individuals.

322
323 Our analyses also showed that prior herpes zoster events had a small positive association with
324 anti-IFN-I autoAb development ($p=0.01466$; **Fig. 4B**). This was particularly surprising, as further
325 temporal analysis revealed that the prior recorded herpes zoster diagnoses did not always
326 immediately precede the onset of anti-IFN-I autoAb development, as might be expected if the
327 severe acute disease itself triggered autoAb production. Specifically, out of the 12 individuals
328 who developed anti-IFN-I autoAbs and had documented prior herpes zoster, only two individuals
329 (P10 and P24) had herpes zoster in the six months prior to first detection of anti-IFN-I autoAbs.
330 Of the remaining 10 individuals, the herpes zoster events were recorded variously between three
331 and 14 years prior to anti-IFN-I autoAb onset. However, it is possible that the recorded herpes
332 zoster events might act as a well-documented indicator of other disparate types of severe
333 infections that may also have occurred in these patients, perhaps closer to the time of anti-IFN-I
334 autoAb development. In this regard, it is notable that a previous study postulated that a range of
335 recurrent severe or chronic infections may be factors in promoting the development of autoAbs,
336 including against IFN-I, in certain infection-susceptible immunodeficient individuals (Walter et
337 al., 2015). To explore this further on a case-by-case basis in our sub-cohort, we looked for

338 additional recorded infection-related clinical events that occurred up to one year prior to first
339 detection of anti-IFN-I autoAbs. One individual (P4) was reported to have recently suffered from
340 a severe pneumonia with sepsis that led to hospitalization. Respiratory samples taken from P4
341 at this time were found to be PCR-positive for influenza A virus and bocavirus, the former agent
342 being paradigmatic for inducing significant IFN-I responses (Dunning et al., 2018). Another
343 individual (P7) was treated for HCV infection with ribavirin and pegylated IFN α , but the normal
344 course of treatment was cut short for an unknown reason, and P7 developed anti-IFN α 2
345 autoAbs during this period. Thus, our finding of a small, yet statistically significant, association
346 between prior herpes zoster diagnoses and anti-IFN-I autoAb development, together with
347 additional case-by-case analyses of individual infection-related events, may support the concept
348 that previous infections might influence autoAb induction (Walter et al., 2015). Mechanistically,
349 as discussed below for the IFN α -treated individual (P7), this could be due to events that
350 increase levels of the IFN-I ‘immunogen’ for subsequent autoAb development, which could
351 include severe infections.

352

353 **Pre-existing autoimmune reactivity predicts subsequent anti-IFN-I autoAb development.**

354 While exposure to virus-induced IFN-I may act as the ‘immunogen’ for triggering anti-IFN-I
355 autoAb production, a compromised ability to tolerate self-antigens, including IFN-I, is likely an
356 essential additional requirement for autoAb development. For example, defects in genes relating
357 to correct thymus function, key to self-tolerance mechanisms, have been clearly linked to the
358 early lifetime development of anti-IFN-I autoAbs (Bodansky et al., 2022; Le Voyer et al., 2023;
359 Meager et al., 2006; Ramakrishnan et al., 2018). Furthermore, in the elderly, it may be that
360 common age-related thymic decline plays a key role in reducing self-tolerance and promoting
361 autoAb development in some individuals (Liang et al., 2022). Given the availability of longitudinal
362 clinical data and samples for our sub-cohort, we speculated that further analysis may reveal
363 evidence of general loss of self-tolerance that precedes induction of anti-IFN-I autoAbs in certain

364 patients. We therefore initially searched the available clinical records of patients we had
365 analysed for anti-IFN-I autoAbs to identify instances where their autoimmune status had been
366 assessed by ANA (anti-nuclear antigen) test. While the number of patients tested due to clinical
367 need was small (n=4 for those with anti-IFN-I autoAbs, n=12 for matched controls), there was
368 nevertheless a statistically significant association between prior ANA test positivity and
369 subsequent development of anti-IFN-I autoAbs in our sub-cohort ($p = 0.02692$; **Fig. 4C**). To test
370 the association between loss of self-tolerance (e.g. ANA positivity) and subsequent anti-IFN-I
371 autoAb induction more formally, we next selected 22 out of our 35 anti-IFN-I autoAb positive
372 patients for whom we had at least 5 years of validated anti-IFN-I autoAb negativity prior to anti-
373 IFN-I autoAb development. For each patient, we obtained the two plasma samples taken
374 immediately before the first confirmed detection of anti-IFN-I autoAbs (this was typically 6
375 months and 1 year prior), and used a multiplexed bead-based assay to screen these samples for
376 IgG autoAbs binding to 19 different human autoantigens associated with autoimmune disease,
377 including those likely detected by the clinical ANA test. In parallel, age-matched samples from 22
378 (negative) patients who never developed anti-IFN-I autoAbs were also tested. Using standard
379 deviation thresholds based on these negative patient samples, we identified 11 patients with IgG
380 autoAbs targeting diverse ANA-related and non-related autoantigens, and it was striking that all
381 of these 11 patients (100%) were positive individuals who subsequently went on to develop anti-
382 IFN-I autoAbs (**Fig. 4D**). None of the 22 anti-IFN-I autoAb negative patients exhibited
383 autoreactivity to these other autoantigens. There was no apparent specificity to the observed
384 prior autoreactivity in those who went on to develop anti-IFN-I autoAbs, with different patients
385 harboring IgG targeting distinct autoantigens (including β 2-GPI, Ku, Mi-2, PCNA, RNP, RNP/Sm,
386 SSA/Ro60, and SSB/La). However, it is interesting to note that anti-SSA and anti-SSB autoAbs
387 are associated with primary Sjögren's syndrome where frequent development of anti-IFN-I
388 autoAbs has been reported (Burbelo et al., 2019; Gupta et al., 2016). These data amounted to a
389 statistically highly significant association between prior autoimmune autoAb positivity and

390 subsequent development of anti-IFN-I autoAbs ($p = 0.0009766$; **Fig. 4E**). Overall, the statistically
391 significant association between prior ANA test positivity and subsequent development of anti-
392 IFN-I autoAbs, together with our experimental identification of autoreactivity in 50% of those who
393 went on to produce anti-IFN-I autoAbs, indicate that diminished self-tolerance can precede anti-
394 IFN-I autoAb development. Furthermore, these data suggest that those with certain autoimmune
395 diseases, which might be detectable by routine assays such as ANA screening, are at higher
396 risk of subsequently developing anti-IFN-I autoAbs.

397
398 **Development and lifelong persistence of neutralizing anti-IFN α autoAbs potentially**
399 **triggered by therapeutic IFN α in an individual with pre-existing autoimmunity.**

400 Based on previous hypotheses (Hale, 2023), and the data presented so far in this manuscript,
401 we postulate that anti-IFN-I autoAbs develop following exposure to unusually high levels of IFN-I
402 (possibly driven by severe infection) in the context of diminished self-tolerance. Towards
403 validating this concept, we followed-up on the case of individual P7, who developed neutralizing
404 anti-IFN α autoAbs in their mid-50s, and maintained them lifelong ever since (>12 years) (**Fig.**
405 **5A**). P7 was initially diagnosed with HCV in their mid-40s, and was treated with the standard of
406 care at the time, ribavirin and pegylated IFN α , eight years later. Treatment with pegylated IFN α
407 was started only 5 weeks before neutralizing anti-IFN α autoAbs were first detected, and all
408 previous samples tested (>12 years) were negative for anti-IFN α autoAbs (**Fig. 5A**). This
409 observation is highly suggestive that the treatment of P7 with pegylated IFN α may have
410 stimulated the production of long-lasting anti-IFN α autoAbs in a manner similar to that previously
411 reported in a single case (Jorns et al., 2006). However, such occurrences would seem to be the
412 atypical situation, as although production of anti-IFN α autoAbs has been described to occur in
413 response to recombinant IFN α treatment, production appears to be transient and usually self-
414 resolving, at least in the small numbers of individuals (20-40) tested previously (Bell et al., 1994;
415 Jorns et al., 2006; Ronnblom et al., 1992). To formally address this on a larger scale, we took

416 advantage of our access to plasma samples taken from 300 individuals in the SHCS (including
417 P7; **Supplementary Table 1**) who had been treated with pegylated IFN α , and assessed whether
418 they had detectable levels of anti-IFN-I IgG autoAbs. Two samples per patient were tested: the
419 first sample available after IFN α treatment began (typically around 6 months); and the last
420 sample available (typically 10-20 years later). Only 3/300 individuals tested around 6 months
421 after starting IFN α treatment were confirmed to possess anti-IFN α IgG autoAbs in their plasmas
422 (P7, P37, and P38), and only the plasma of P7 neutralized the activity of IFN α (**Fig. 5B**). For
423 P37 and P38, the presence of anti-IFN α autoAbs was transient, as these autoAbs were not
424 readily detected in the last available plasma samples from these patients, or in any other
425 longitudinal samples available (spanning up to 20 years) (**Figs. 5B-D**). Analysis of the last
426 available plasma samples from our IFN α -treated cohort revealed that only 2/300 individuals
427 possessed anti-IFN α autoAbs in their plasmas at this timepoint, and both neutralized the activity
428 of IFN α (P7 and P36) (**Fig. 5B**). Notably, longitudinal analysis of biobanked plasma samples
429 from P36 (spanning around 15 years) revealed that his induction of anti-IFN α IgG autoAbs
430 occurred about 10 years after IFN α treatment stopped, suggesting that the IFN α treatment was
431 not the acute trigger for anti-IFN α autoAbs in this individual. We also (re)-tested all available
432 longitudinal plasma samples from 5 negative individuals treated with IFN α in case we had
433 missed important sample timepoints. However, despite some low-level transient anti-IFN α IgG
434 autoAb positive 'blips', all these IFN α -treated individuals remained negative for long-lasting
435 neutralizing anti-IFN α autoAbs (**Fig. 5E**). Thus, we conclude that development of long-lasting
436 neutralizing anti-IFN α autoAbs in response to IFN α treatment (as observed for P7) is an atypical,
437 rare event.

438
439 Towards understanding why P7 (but none of the other IFN α -treated individuals) developed a
440 long-lasting neutralizing anti-IFN α IgG autoAb response during treatment, we obtained the two
441 plasma samples taken immediately prior to IFN α treatment (typically 6 months and 1 year prior)

442 for seven IFN α -treated individuals in addition to P7. We then used a multiplexed bead-based
443 assay to screen these samples for IgG autoAbs binding to a panel of different autoimmune
444 disease-associated autoantigens as a means to identify those with potential breakdown of self-
445 tolerance at these timepoints. Notably, P7 had strong unambiguous evidence for autoimmune
446 reactivity (anti- β 2-GPI IgG autoAbs) in his plasma samples prior to developing anti-IFN α
447 autoAbs, while autoreactivity was generally lacking in samples taken from all other patients who
448 did not develop anti-IFN α autoAbs following IFN α treatment (except N36 who had weak
449 reactivity to SSB/La) (**Fig. 5F**). Furthermore, longitudinal analysis revealed that P7 possessed
450 anti- β 2-GPI IgG autoAbs at least 3 years prior to receiving IFN α treatment and developing long-
451 lasting neutralizing anti-IFN α IgG (**Fig. 5G**). Taken together with our previous observation of a
452 statistically significant association between prior autoreactivity positivity and subsequent anti-
453 IFN-I autoAb development, the results of this case-study suggest that a pre-existing breakdown
454 of self-tolerance in P7 was likely to have been decisive in him mounting a long-lasting anti-IFN α
455 IgG response when treated with pegylated IFN α .

456

457

DISCUSSION

458

459 Herein, we systematically investigated the age- and IFN-I-treatment -related development, long-
460 term dynamics, and longevity of anti-IFN-I autoAbs in well-treated individuals enrolled over
461 several decades in the Swiss HIV Cohort Study (SHCS). The unique aspect of our work is the
462 longitudinal analysis of historic biobanked patient samples and clinical records that span the
463 decades before and after each patient developed anti-IFN-I autoAbs. Together with retrospective
464 serological and cellular immunoassays, this allowed us to dissect factors associated with anti-
465 IFN-I autoAb induction and their consequences. Our observation that around 1.9% of individuals
466 developed anti-IFN-I autoAbs (1.17% for neutralizing autoAbs only), with a median onset age of
467 ~63 years (range 45-80), aligns exceedingly well with findings from a recent cross-sectional

468 study that noted a sharp increase in neutralizing anti-IFN-I autoAb prevalence (to 1.4%) in
469 otherwise healthy individuals over the age of 70 years, as compared with younger individuals
470 (Bastard et al., 2021). This suggests that the underlying HIV-positive status of individuals within
471 the sub-cohort we studied, the majority of whom were well-treated with long-term antiretroviral
472 therapy, likely has only a limited impact (if any) on anti-IFN-I autoAb development. Our results
473 should therefore also be broadly applicable to the otherwise healthy general aging population,
474 and our data now provide a new high-resolution long-term perspective on this form of IFN
475 system deficiency and its contribution to severe viral disease.

476
477 The induction of anti-IFN-I autoAbs in some individuals around ages 60-65 is enigmatic. Such
478 late-onset development is suggestive that, at least in this population, germline host genetic
479 variants compromising thymic function may play only a limited contribution as compared with the
480 situation in other younger patient populations described to harbor mutations in *AIRE* or
481 alternative NF- κ B pathway genes (Le Voyer et al., 2023; Meager et al., 2006). Nevertheless, our
482 finding that there is a significant temporal association between prior autoimmune reactivity (e.g.
483 via a positive clinical ANA test) and the subsequent development of anti-IFN-I autoAbs is still
484 indicative that these patients may indeed have lost their full self-tolerance capacity. While we
485 cannot rule out an impact of the HIV-1 infection on patient autoimmune status (Roszkiewicz and
486 Smolewska, 2016; Zandman-Goddard and Shoenfeld, 2002), we note that the observed anti-
487 IFN-I autoAb prevalence in our sub-cohort is very similar to that in otherwise healthy individuals
488 (Bastard et al., 2021). Given the genetic link between central T-cell tolerance in the thymus and
489 anti-IFN-I autoAb development (Le Voyer et al., 2023; Meager et al., 2006), the most likely
490 explanation in our aged patients is therefore that the natural process of thymic involution has led
491 to reduced thymus activity and thus an overall increased likelihood of general development of
492 autoimmunity (Liang et al., 2022), including against IFN-I. Further studies will have to address
493 this hypothesis directly, as well as understand why only a subset of aged individuals go on to

494 develop such autoimmune reactions. In this regard, the availability of longitudinal biobanked
495 plasma and PBMC samples, together with high-resolution tracking of anti-IFN-I autoAb induction
496 (such as presented here), could prove invaluable to retrospectively assess thymus-related
497 immunosenescence in specific aging individuals by assaying historic thymic output (e.g. by
498 quantifying T-cell receptor excision circles, TRECs; (Mitchell et al., 2010)) and correlating this
499 directly with the subsequent likelihood of anti-IFN-I autoAb induction. Given the apparent severe
500 consequences of anti-IFN-I autoAbs for infection susceptibility (reviewed in (Bastard et al.,
501 2024a; Hale, 2023)), in the future there may be a clear clinical role for performing diagnostic
502 autoimmune (e.g. ANA test and others) or TREC quantifications to help predict an individual's
503 risk of developing this form of IFN system deficiency.

504
505 While aging and prior autoimmune reactivity appear to pre-dispose an individual to develop anti-
506 IFN-I autoAbs, the 'two-hit' hypothesis suggests that (auto)immunization with IFN-I is a
507 subsequently required trigger in this process (Hale, 2023). Our finding of a statistical association
508 (albeit weak) between prior recorded virus infections such as reactivated herpes zoster, which
509 activates a clear endogenous IFN-I response in patients (Vandoren et al., 2024), and
510 development of anti-IFN-I autoAbs provides some support to the idea that autoimmunization
511 may occur. Similar support comes from our anecdotal finding that anti-IFN-I autoAbs developed
512 in a patient immediately following hospitalization with severe pneumonia possibly caused by
513 influenza A virus, again a scenario where endogenous IFN-I and inflammatory responses will be
514 activated (Dunning et al., 2018). We also cannot rule out that a subset of our patients had
515 specific sub-clinical undiagnosed systemic autoimmune diseases, such as primary Sjögren's
516 syndrome or systemic lupus erythematosus, which provided an environment where both loss of
517 tolerance and atypically increased levels of IFN-I triggered anti-IFN-I autoAb development
518 (Burbelo et al., 2019; Gupta et al., 2016; Mathian et al., 2022; Trutschel et al., 2022). However,
519 additional evidence supporting the 'two-hit' hypothesis comes from our analysis of 300

520 individuals who were treated (or ‘immunized’) with pegylated IFN α , where we identified that a
521 single individual with unambiguous evidence for loss of self-tolerance prior to therapy was the
522 only individual to generate long-lasting neutralizing anti-IFN α IgG in response to the exogenous
523 IFN α . Overall, this could suggest that some previous acute infections in tolerance-compromised
524 individuals might lead to development of anti-IFN-I autoAbs, and could thus have long-term
525 consequences for enhancing susceptibility to future severe infections. This concept may also
526 apply to some individuals who are still treated therapeutically with IFN-Is (EASL, 2023), and
527 given the ‘two-hit’ hypothesis it may be worth considering future implementation of diagnostic
528 autoimmune pre-screening and risk-benefit evaluations to assess the likely short- and long- term
529 outcomes associated with IFN-I treatment specifically in those with poor self-tolerance.

530
531 In contrast to previous cross-sectional studies (Abers et al., 2021; Bastard et al., 2020; Kisand et
532 al., 2008; Koning et al., 2021; Lopez et al., 2021; van der Wijst et al., 2021; Wang et al., 2021),
533 our access to high-resolution longitudinal samples gave us the unique opportunity to study the
534 within-individual consequences of neutralizing anti-IFN-I autoAb development. Compared to
535 samples taken from before anti-IFN-I autoAbs were detectable, we observed a clear temporal
536 correlation between induction of neutralizing anti-IFN α 2 autoAbs and a reduction of baseline ISG
537 levels in patient PBMCs. It is logical to assume that the appearance and maintenance of these
538 neutralizing autoAbs led to this functional impairment of innate antiviral immunity, thus
539 contributing to an increased susceptibility to severe viral infections as previously reported
540 (reviewed in (Bastard et al., 2024a; Hale, 2023)). The consequences of harboring other
541 neutralizing anti-IFN-I autoAbs (e.g. against IFN β or IFN ω) could not be readily discerned in our
542 sub-cohort due to the relatively low numbers of positive individuals identified, although a recent
543 report suggests that neutralization of IFN α may have greater pathogenic consequences than
544 neutralization of IFN ω (Bastard et al., 2024b). Nevertheless, a key finding from our work was the
545 observation that following induction, neutralizing anti-IFN-I autoAbs can be effectively

546 maintained in the circulation lifelong (over at least 15 years in one individual), meaning that the
547 consequences of anti-IFN-I development could result in extremely long-lasting IFN-I functional
548 deficiency and increased susceptibility to infection. Transient induction of anti-IFN-I autoAbs has
549 been described in some infection scenarios (Chang et al., 2021; Steels et al., 2022), as well as
550 in this study, and could potentially have important physiological regulatory functions such as
551 dampening immunopathologies (Babcock et al., 2024). However, a distinction should be made
552 with the class of long-lasting, lifelong neutralizing anti-IFN-I autoAbs that we mainly describe
553 here, and which functionally impair innate antiviral immunity.

554
555 Our study has some limitations, including the retrospective nature and potential biases inherent
556 in long-term cohort studies. For example, as the SHCS was not specifically established to study
557 clinical aspects of autoAbs, autoimmune results (e.g. ANA tests) were only available for some
558 patients that were performed based on clinical need. However, we were able to address this
559 specific deficiency through systematic measurements made retrospectively from biobanked
560 samples. Furthermore, not all (viral) infections can be recorded in an observational cohort study,
561 and the low prevalence of neutralizing anti-IFN-I autoAbs limits the power to assess their impact
562 on subsequent infections. While we believe that the results from our work should also be broadly
563 applicable to otherwise healthy general populations, we also acknowledge that all of our study
564 patients are people living with HIV, and we thus cannot rule out potential confounding factors
565 related to the infection, unknown opportunistic co-infections, or the effects of antiretroviral
566 therapy that could limit the generalizability of our study. In this regard, a major limitation to
567 studying the functional consequences of anti-IFN-I autoAbs was actually that we could not
568 effectively assess their impact on HIV-1 replication due to the majority of patients being on long-
569 term antiretroviral therapy and therefore exhibiting virological suppression at the time of anti-IFN-
570 I autoAb detection. Our initial sampling strategy (>65 years of age) may also have biased our
571 assessment of anti-IFN-I autoAb lifelong persistence, and we may not yet have a true

572 appreciation of transient anti-IFN-I autoAb induction. While future investigations with larger and
573 more diverse cohorts are therefore clearly essential, we also highlight the unique resource that
574 the SHCS represents for studies such as this given the rarity of decade-spanning longitudinally-
575 sampled aging cohorts focused on infectious diseases with the numbers of patients required to
576 reveal uncommon anti-IFN-I autoAbs.

577
578 In summary, our study provides a comprehensive longitudinal exploration of the age-related
579 development and specificities of anti-IFN-I autoAbs. Our work identifies prior infection and
580 autoimmune factors that influence the likelihood of anti-IFN-I autoAb induction, and thereby
581 supports the hypothesis that at least ‘two-hits’ probably underlie this process. These findings
582 have implications for diagnosing, perhaps through routine screening of ‘at-risk’ individuals with
583 known autoimmune conditions, those who may be pre-disposed to develop anti-IFN-I autoAbs
584 and the lifelong IFN-I functional deficiency that results. Broader knowledge in this area should
585 contribute to the development of targeted strategies to mitigate severe viral disease
586 susceptibility.

587

588

MATERIALS AND METHODS

589

590 **Patient samples, data and ethics.** The 1876 plasma samples from patients >65 years at the
591 time of initial testing (**Supplementary Table 1**), 300 plasma samples from patients treated with
592 pegylated IFN α (**Supplementary Table 1**), and all retrospective follow-up longitudinal samples
593 (including plasma and/or PBMCs) analyzed in this study were derived from samples stored in
594 the biobanks of the Swiss HIV Cohort study (SHCS). The SHCS is a prospective, nationwide,
595 longitudinal, noninterventional, observational, clinic-based cohort with semiannual visits and
596 blood collections, enrolling all PLH in Switzerland since 1988 (Scherrer et al., 2022). The SHCS
597 maintains comprehensive, longitudinal, anonymous data collections for all participants, including

598 extensive clinical and demographic data. The data are collected by the five Swiss university
599 hospitals, two cantonal hospitals, 15 affiliated hospitals and 36 private physicians (listed
600 in <http://www.shcs.ch/180-health-care-providers>). Detailed information on the study is available
601 at <http://www.shcs.ch>. The SHCS has been approved by the ethics committees of all
602 participating institutions (Kantonale Ethikkommission Bern, Ethikkommission des Kantons St.
603 Gallen, Comité Départemental d'Éthique des Spécialités Médicales et de Médecine
604 Communautaire et de Premier Recours, Kantonale Ethikkommission Zürich, Repubblica et
605 Cantone Ticino–Comitato Etico Cantonale, Commission Cantonale d'Étique de la Recherche
606 sur l'Être Humain, Ethikkommission beider Basel), and written informed consent has been
607 obtained from all participants. The personnel who conducted the work with patient samples had
608 no information on patient demographics at the time of analysis, and all data have subsequently
609 been analyzed anonymously.

610 **Analysis of Autoreactive IgG in Plasma Samples.** A previously described high-throughput
611 multiplexed bead-based assay was implemented to assay patient plasma samples for anti-IFN- γ
612 IgG (Achleitner et al., 2024; Busnadiego et al., 2022; Liechti et al., 2018). Briefly, magnetic
613 beads (MagPlex-C Microspheres, Luminex) were coupled to recombinant carrier-free human
614 IFN- α s (IFN α 2, Novus Biologicals; IFN β , PeproTech; or IFN ω , Novus Biologicals) at a
615 concentration of 10 μ g protein per million beads, or left empty. Bead coating efficiency and bead
616 specificity were assessed using mouse monoclonal antibodies as described previously
617 (Busnadiego et al., 2022). For serological testing, obtained patient plasma samples were heat-
618 inactivated at 56°C for 1h before being diluted 1:50 in PBS supplemented with 1% BSA
619 (PBS/BSA) and incubated in 96-well plates with 1:1:1:1 mixtures of IFN α 2:IFN β :IFN ω :empty
620 beads (2x10³ beads per region per well; 1:100 final concentration of plasma). On all
621 experimental plates, a human polyclonal anti-IFN α 2b antiserum (BEI resources) was used as a
622 positive control, and an in-house healthy donor pool of human plasmas was used both as a
623 negative control and for batch normalization. Following incubation of the bead:plasma mixes for

624 1h at room temperature, beads were washed twice with PBS/BSA before phycoerythrin (PE)-
625 labeled secondary antibodies were added separately in PBS/BSA (pan-IgG, 1:500 dilution,
626 Southern Biotech; IgG1, 1:500 dilution, Southern Biotech; IgG2, 1:100 dilution, Southern
627 Biotech; IgG3, 1:100 dilution, Southern Biotech; IgG4, 1:100 dilution, Southern Biotech). After a
628 further 1h incubation at room temperature, bead mixtures were washed twice in PBS/BSA and
629 samples were analyzed on a FlexMap 3D instrument (Luminex). A minimum of 50 beads per
630 antigen were acquired. For each plasma sample, Median Fluorescence Intensity (MFI) values
631 from the IFN-I-coated beads were obtained and made relative to the corresponding MFI value
632 obtained from the empty beads (fold over empty, FOE). Values were then normalized between
633 plates and cohorts using results from the in-house healthy donor pool. In initial screenings,
634 patient plasmas exhibiting normalized FOE values >2 MFI were considered positive for the
635 specific anti-IFN-I IgG. Available longitudinal plasma samples were then obtained for re-testing
636 of all positive patients and selected negative patients. When assaying longitudinal samples,
637 patient plasmas exhibiting normalized FOE values >10 standard deviations (SDs) above the
638 mean MFIs of the first 5 available samples from each individual patient were considered positive
639 for the specific anti-IFN-I IgG.

640
641 To assay patient plasma samples for IgG targeting various human autoantigens associated with
642 autoimmune diseases, a customized 19 autoantigen-containing MILLIPLEX® Human
643 Autoimmune Autoantibody Panel (Merck Millipore) was used. The assay was performed
644 according to the manufacturer's protocol using a 1:300 final dilution of each heat-inactivated
645 patient plasma, and samples were analyzed on a FlexMap 3D instrument (Luminex). For each
646 plasma sample, FOE MFI values for IgG targeting each autoantigen were calculated as
647 described above. Within the dataset for each autoantigen, FOE values were then normalized to
648 the mean MFI values obtained from the anti-IFN-I autoAb-negative patient samples. Patient
649 plasmas exhibiting normalized FOE values >5 SDs above the mean MFIs obtained from the anti-

650 IFN-I autoAb-negative patient samples were considered positive for the specific anti-autoantigen
651 IgG.

652

653 **Analysis of IFN-I Neutralization in Plasma Samples.** IFN-I neutralization was assessed as
654 described previously using a 293T transient-transfection based dual-luciferase reporter assay in
655 96-well plates that is based around co-transfection of a plasmid containing the firefly luciferase
656 (FF-Luc) gene under control of the IFN-inducible mouse *Mx1* promoter (pGL3-Mx1P-FFLuc)
657 (kindly provided by Georg Kochs) with a plasmid constitutively expressing the *Renilla* luciferase
658 (Ren-Luc) gene (pRL-TK-Renilla) (Busnadiego et al., 2022). Twenty-four hours post-transfection
659 of both plasmids, heat-inactivated patient plasma samples (or multiple negative controls) were
660 diluted 1:50 in DMEM supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin and
661 100 mg/mL streptomycin, and incubated for 1h at room temperature with 10, 1 or 0.2 ng/mL of
662 IFN α 2 or IFN ω , or with 1, 0.2 or 0.04 ng/mL of IFN β , prior to their addition to the transfected
663 cells. After 24h, cells were lysed for 15 min at room temperature and FF-Luc and Ren-Luc
664 activity levels were determined using the Dual-Luciferase Reporter Assay System (Promega)
665 and a PerkinElmer EnVision plate reader (EV2104) according to the manufacturers' instructions.
666 FF-Luc values were normalized to Ren-Luc values and then to the median luminescence
667 intensity of control wells that had not been stimulated with any IFN-I. Patient plasmas that
668 reduced IFN-I-stimulated FF-Luc/Ren-Luc values by >2 SDs below the mean values of the
669 negative control samples were considered to be neutralizing.

670

671 **Analysis of ISG Expression in PBMC Samples.** Thirteen patients who developed persistent
672 neutralizing anti-IFN α autoAbs (positive patients) were selected, together with 13 age-matched
673 control patients who were confirmed longitudinally to have never developed anti-IFN-I autoAbs
674 (negative patients). For each positive patient, we obtained biobanked frozen PBMC samples
675 corresponding to 2-3 annual donations given before development of anti-IFN α autoAbs and 2-3

676 annual donations given after development of autoAbs. For each negative patient, we obtained
677 similar biobanked frozen PBMC samples corresponding to equivalent timepoints. Total RNA
678 from freshly thawed PBMCs was extracted using the ReliaPrep™ RNA Cell Miniprep System
679 (Promega), and mRNA was subsequently reverse transcribed into cDNA with an oligo(dT)
680 primer using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) according to the
681 manufacturer's instructions. Real-time PCR was then performed with PowerTrack™ SYBR
682 Green Master Mix (Thermo Fisher Scientific) using gene-specific forward and reverse primers
683 (sequences available upon request) in a 7300 Real-Time PCR System (Applied Biosystems).
684 Relative gene expression was calculated with the $\Delta\Delta C_t$ method. Data were normalized to
685 *GAPDH* levels, averaged between the 2-3 annual donations per patient and per timepoint, and
686 were expressed as percent change relative to the first timepoint (i.e. before development of anti-
687 IFN α autoAbs for the positive patients, or to the equivalent timepoint for the age-matched
688 negative patients). Statistical significance was determined based on the ΔC_t values (normalized
689 to *GAPDH*) using a Mann-Whitney U test.

690
691 **Statistical Analyses.** Patient clinical and demographic data derived from the SHCS relating to
692 the content of Supplementary Tables 1-3, blood cell compositions, prior CMV positivity, prior
693 herpes zoster diagnoses, and prior ANA test positivity were examined using the Wilcoxon rank-
694 sum test (for continuous variables), or Fisher's exact test (for categorical variables). In addition,
695 conditional logistic regression models were performed to take into account the effect of matching
696 cases and controls. Analyses were performed using R version 4.2.2., with statistical tests noted
697 in the appropriate figure legends. All other statistical analyses presented were performed in
698 GraphPad Prism 9 using the statistical tests noted in the appropriate figure legends.

699

700

ACKNOWLEDGMENTS

701

702 We thank the patients participating in the SHCS and their physicians and study nurses for
703 patient care. The members of the SHCS are Abela IA, Aebi-Popp K, Anagnostopoulos A,
704 Battegay M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier
705 G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF (President of the SHCS),
706 Hachfeld A, Haerry D (Deputy of 'Positive Council'), Hasse B, Hirsch HH, Hoffmann M, Hösli I,
707 Huber M, Jackson-Perry D (patient representative), Kahlert CR (Chairman of the Mother & Child
708 Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Kusejko K (Head of Data
709 Centre), Labhardt N, Leuzinger K, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N,
710 Nemeth J, Nicca D, Notter J, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the
711 Scientific Board), Salazar-Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical
712 and Laboratory Committee), Tarr P, Trkola A, Wandeler G, Weisser M, and Yerly S. We are
713 grateful to Nadine Rist, Stefan Schmutz, and Kevin Steiner (University of Zurich, Switzerland) for
714 technical support and sample management. We are also grateful to Alexandra Calmy (University
715 of Geneva, Switzerland) and to Matthias Cavassini (University of Lausanne, Switzerland) for
716 their support as representatives of SHCS centers. Financial support for this study was provided
717 by the Swiss National Science Foundation (SNF; grants 31003A_182464 and 310030_214957
718 to BGH), the Novartis Foundation for Medical-Biological Research (grant 23A069 to BGH), and
719 the Promedica Foundation (to IAA). The study was also co-financed within the framework of the
720 Swiss HIV Cohort Study (SHCS), supported by the SNF (33CS30_201369 to HFG), by the small
721 nested SHCS project 898 (to BGH and IAA). The funders had no role in study design, data
722 collection and analysis, decision to publish, or preparation of the manuscript. The authors
723 declare no competing financial interests.

724

725

CONFLICT OF INTEREST STATEMENT

726

727 IAA received the Swiss Fellowship Gilead research grant and participated in advisory boards
728 from Astra Zeneca and Moderna. EB received travel grants and payments for participation in
729 advisory boards from Gilead Sciences, MSD, ViiV Healthcare, Pfizer, Abbvie, Astra Zeneca,
730 Moderna and Ely Lilly. AR received support for advisory boards and/or travel grants from MSD,
731 Gilead Sciences, Pfizer and Moderna. HFG received unrestricted research grants from Gilead
732 Sciences; fees for data and safety monitoring board membership from Merck;
733 consulting/advisory board membership fees from Gilead Sciences, Merck, Johnson and
734 Johnson, Janssen, GSK, Novartis and ViiV Healthcare; and grants from the Swiss National
735 Science Foundation, the Bill and Melinda Gates Foundation, the Yvonne Jacob Foundation,
736 Gilead Sciences, ViiV Healthcare and the National Institutes of Health. All the reported grants
737 and remuneration were provided outside the context of this work. All other authors did not report
738 any disclosures.

739 REFERENCES

- 740
- 741 Abers, M.S., L.B. Rosen, O.M. Delmonte, E. Shaw, P. Bastard, L. Imberti, V. Quaresima, A. Biondi, P.
742 Bonfanti, R. Castagnoli, J.L. Casanova, H.C. Su, L.D. Notarangelo, S.M. Holland, and M.S.
743 Lionakis. 2021. Neutralizing type-I interferon autoantibodies are associated with delayed viral
744 clearance and intensive care unit admission in patients with COVID-19. *Immunology and cell*
745 *biology* 99:917-921.
- 746 Achleitner, M., N.K. Mair, J. Danhardt, R. Kardashi, M.A. Puhan, I.A. Abela, N. Toepfner, K. de With, W.
747 Kanczkowski, N. Jarzebska, R.N. Rodionov, C. Wolf, M.A. Lee-Kirsch, C. Steenblock, B.G. Hale,
748 and S.R. Bornstein. 2024. Absence of Type I Interferon Autoantibodies or Significant Interferon
749 Signature Alterations in Adults With Post-COVID-19 Syndrome. *Open Forum Infect Dis* 11:ofad641.
- 750 Akbil, B., T. Meyer, P. Stubbemann, C. Thibeault, O. Staudacher, D. Niemeyer, J. Jansen, B. Muhlemann,
751 J. Doehn, C. Tabeling, C. Nussag, C. Hirzel, D.S. Sanchez, A. Nieters, A. Lothar, D. Duerschmied,
752 N. Schallner, J.N. Lieberum, D. August, S. Rieg, V. Falcone, H. Hengel, U. Kolsch, N. Unterwalder,
753 R.H. Hubner, T.C. Jones, N. Suttorp, C. Drosten, K. Warnatz, T. Spinetti, J.C. Schefold, T. Dorner,
754 L.E. Sander, V.M. Corman, U. Merle, C.s.G. Pa, F. Kurth, H. von Bernuth, C. Meisel, and C.
755 Goffinet. 2022. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I
756 Interferon Auto-antibodies. *Journal of clinical immunology* 42:1111-1129.
- 757 Alotaibi, F., N.K. Alharbi, L.B. Rosen, A.Y. Asiri, A.M. Assiri, H.H. Balkhy, M. Al Jeraisy, Y. Mandourah, S.
758 AlJohani, S. Al Harbi, H.A.A. Jokhdar, A.M. Deeb, Z.A. Memish, J. Jose, S. Ghazal, S. Al Faraj,
759 G.A. Al Mekhlafi, N.M. Sherbeeni, F.E. Elzein, B.M. AlMutairi, A. Al-Dawood, M.L. Abdullah, T.
760 Barhoumi, M.W. Alenazi, A. Almasood, S.M. Holland, Y.M. Arabi, and G. Saudi Critical Care Trials.

- 761 2023. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory
762 syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE
763 clinical trial. *Influenza Other Respir Viruses* 17:e13116.
- 764 Babcock, B.R., A. Kusters, D.J. Eddins, M.S.B. Donaire, S. Sarvadhavabhatla, V. Pae, F. Beltran, V.W.
765 Murray, G. Gill, G. Xie, B.S. Dobosh, V.D. Giacalone, R.M. Tirouvanziam, R.P. Ramonell, S.A.
766 Jenks, I. Sanz, F.E.-H. Lee, N.R. Roan, S.A. Lee, and E.E.B. Ghosn. 2024. Transient anti-interferon
767 autoantibodies in the airways are associated with efficient recovery from COVID-19. *medRxiv*
768 2024.2001.2011.24301000.
- 769 Bastard, P., A. Gervais, T. Le Voyer, Q. Philippot, A. Cobat, J. Rosain, E. Jouanguy, L. Abel, S.Y. Zhang,
770 Q. Zhang, A. Puel, and J.L. Casanova. 2024a. Human autoantibodies neutralizing type I IFNs: From
771 1981 to 2023. *Immunol Rev*
- 772 Bastard, P., A. Gervais, T. Le Voyer, J. Rosain, Q. Philippot, J. Manry, E. Michailidis, H.H. Hoffmann, S.
773 Eto, M. Garcia-Prat, L. Bizien, A. Parra-Martinez, R. Yang, L. Haljasmagi, M. Migaud, K.
774 Sarekannu, J. Maslovskaja, N. de Prost, Y. Tandjaoui-Lambiotte, C.E. Luyt, B. Amador-Borrero, A.
775 Gaudet, J. Poissy, P. Morel, P. Richard, F. Cognasse, J. Troya, S. Trouillet-Assant, A. Belot, K.
776 Saker, P. Garcon, J.G. Riviere, J.C. Lagier, S. Gentile, L.B. Rosen, E. Shaw, T. Morio, J. Tanaka,
777 D. Dalmiau, P.L. Tharoux, D. Sene, A. Stepanian, B. Megarbane, V. Triantafyllia, A. Fekkar, J.R.
778 Heath, J.L. Franco, J.M. Anaya, J. Sole-Violan, L. Imberti, A. Biondi, P. Bonfanti, R. Castagnoli,
779 O.M. Delmonte, Y. Zhang, A.L. Snow, S.M. Holland, C. Biggs, M. Moncada-Velez, A.A. Arias, L.
780 Lorenzo, S. Boucherit, B. Coulibaly, D. Anglicheau, A.M. Planas, F. Haerynck, S. Duvlis, R.L.
781 Nussbaum, T. Ozcelik, S. Keles, A.A. Bousfiha, J. El Bakkouri, C. Ramirez-Santana, S. Paul, Q.
782 Pan-Hammarstrom, L. Hammarstrom, A. Dupont, A. Kurolap, C.N. Metz, A. Aiuti, G. Casari, V.
783 Lampasona, F. Ciceri, L.A. Barreiros, E. Dominguez-Garrido, M. Vidigal, M. Zatz, D. van de Beek,
784 S. Sahanic, I. Tancevski, Y. Stepanovskyy, O. Boyarchuk, Y. Nukui, M. Tsumura, L. Vidaur, S.G.
785 Tangye, S. Burrell, D. Duffy, L. Quintana-Murci, A. Klocperk, N.Y. Kann, A. Shcherbina, Y.L. Lau, D.
786 Leung, M. Coulangeat, J. Marlet, R. Koning, L.F. Reyes, A. Chauvineau-Grenier, F. Venet, G.
787 Monneret, M.C. Nussenzweig, R. Arrestier, I. Boudhabhay, H. Baris-Feldman, D. Hagin, J. Wauters,
788 I. Meyts, A.H. Dyer, S.P. Kellenly, N.M. Bourke, R. Halwani, N.S. Sharif-Askari, K. Dorgham, J.
789 Sallette, S.M. Sedkaoui, S. Alkhatir, R. Rigo-Bonnin, F. Morandeira, L. Roussel, D.C. Vinh, S.R.
790 Ostrowski, A. Condino-Neto, C. Prando, A. Bonradenko, A.N. Spaan, L. Gilardin, J. Fellay, S.
791 Lyonnet, K. Bilguvar, R.P. Lifton, S. Mane, H. Lab, C. Clinicians, C.-S. Clinicians, N.I.R.t.C. Group,
792 N.-C.S. Group, C. Danish, S. Danish Blood Donor, H. St. James's, S.C.I. group, C.C.S.G. French,
793 C.-G. Imagine, C. Milieu Interieur, V.C.C. Co, U.M.C.C. Amsterdam, I. Biobank, C.H.G. Effort, C.
794 cohort, C.D. Study, H.-C. Cerba, g. Etablissement du Sang study, M.S. Anderson, B. Boisson, V.
795 Beziat, S.Y. Zhang, E. Vandreakos, O. Hermine, A. Pujol, P. Peterson, T.H. Mogensen, L. Rowen,
796 J. Mond, S. Debette, X. de Lamballerie, X. Duval, F. Mentre, M. Zins, P. Soler-Palacin, R. Colobran,
797 G. Gorochov, X. Solanich, S. Susen, J. Martinez-Picado, D. Raoult, M. Vasse, P.K. Gregersen, L.
798 Piemonti, C. Rodriguez-Gallego, L.D. Notarangelo, H.C. Su, K. Kisand, S. Okada, A. Puel, E.
799 Jouanguy, C.M. Rice, P. Tiberghien, Q. Zhang, A. Cobat, L. Abel, and J.L. Casanova. 2021.
800 Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years
801 old and account for ~20% of COVID-19 deaths. *Science immunology* 6:
- 802 Bastard, P., A. Gervais, M. Taniguchi, L. Saare, K. Sarekannu, T. Le Voyer, Q. Philippot, J. Rosain, L.
803 Bizien, T. Asano, M. Garcia-Prat, A. Parra-Martinez, M. Migaud, M. Tsumura, F. Conti, A. Belot,
804 J.G. Riviere, T. Morio, J. Tanaka, E. Javouhey, F. Haerynck, S. Duvlis, T. Ozcelik, S. Keles, Y.
805 Tandjaoui-Lambiotte, S. Escoda, M. Husain, Q. Pan-Hammarstrom, L. Hammarstrom, G. Ahlijah, A.
806 Abi Haidar, C. Soudee, V. Arseguet, H. Abolhassani, S. Sahanic, I. Tancevski, Y. Nukui, S.
807 Hayakawa, G.P. Chrousos, A. Michos, E.B. Tatsi, F. Filippatos, A. Rodriguez-Palmero, J. Troya, I.
808 Tipu, I. Meyts, L. Roussel, S.R. Ostrowski, L. Schidlowski, C. Prando, A. Condino-Neto, N. Cheikh,
809 A.A. Bousfiha, J. El Bakkouri, C. Clinicians, G.-C.S. Group, C.H.G. Effort, P. Peterson, A. Pujol, R.
810 Levy, P. Quartier, D.C. Vinh, B. Boisson, V. Beziat, S.Y. Zhang, A. Borghesi, A. Pession, E.
811 Andreakos, N. Marr, A.A. Mentis, T.H. Mogensen, C. Rodriguez-Gallego, P. Soler-Palacin, R.
812 Colobran, V. Tillmann, B. Neven, S. Trouillet-Assant, P. Brodin, L. Abel, E. Jouanguy, Q. Zhang, F.
813 Martinon-Torres, A. Salas, A. Gomez-Carballa, L.I. Gonzalez-Granado, K. Kisand, S. Okada, A.
814 Puel, A. Cobat, and J.L. Casanova. 2024b. Higher COVID-19 pneumonia risk associated with anti-
815 IFN-alpha than with anti-IFN-omega auto-Abs in children. *The Journal of experimental medicine*
816 221:

- 817 Bastard, P., L.B. Rosen, Q. Zhang, E. Michailidis, H.H. Hoffmann, Y. Zhang, K. Dorgham, Q. Philippot, J.
818 Rosain, V. Beziat, J. Manry, E. Shaw, L. Haljasmagi, P. Peterson, L. Lorenzo, L. Bizien, S. Trouillet-
819 Assant, K. Dobbs, A.A. de Jesus, A. Belot, A. Kallaste, E. Catherinot, Y. Tandjaoui-Lambiotte, J. Le
820 Pen, G. Kerner, B. Bigio, Y. Seeleuthner, R. Yang, A. Bolze, A.N. Spaan, O.M. Delmonte, M.S.
821 Abers, A. Aiuti, G. Casari, V. Lampasona, L. Piemonti, F. Ciceri, K. Bilguvar, R.P. Lifton, M. Vasse,
822 D.M. Smadja, M. Migaud, J. Hadjadj, B. Terrier, D. Duffy, L. Quintana-Murci, D. van de Beek, L.
823 Roussel, D.C. Vinh, S.G. Tangye, F. Haerynck, D. Dalmau, J. Martinez-Picado, P. Brodin, M.C.
824 Nussenzweig, S. Boisson-Dupuis, C. Rodriguez-Gallego, G. Vogt, T.H. Mogensen, A.J. Oler, J. Gu,
825 P.D. Burbelo, J.I. Cohen, A. Biondi, L.R. Bettini, M. D'Angio, P. Bonfanti, P. Rossignol, J. Mayaux,
826 F. Rieux-Laucat, E.S. Husebye, F. Fusco, M.V. Ursini, L. Imberti, A. Sottini, S. Paghera, E. Quiros-
827 Roldan, C. Rossi, R. Castagnoli, D. Montagna, A. Licari, G.L. Marseglia, X. Duval, J. Ghosn, H.
828 Lab, N.-U.I.R.t.C. Group, C. Clinicians, C.-S. Clinicians, C.G. Imagine, C.C.S.G. French, C. Milieu
829 Interieur, V.C.C. Co, U.M.C.C.-B. Amsterdam, C.H.G. Effort, J.S. Tsang, R. Goldbach-Mansky, K.
830 Kisand, M.S. Lionakis, A. Puel, S.Y. Zhang, S.M. Holland, G. Gorochoy, E. Jouanguy, C.M. Rice, A.
831 Cobat, L.D. Notarangelo, L. Abel, H.C. Su, and J.L. Casanova. 2020. Autoantibodies against type I
832 IFNs in patients with life-threatening COVID-19. *Science* 370:
833
834 Baumann, L., D.L. Braun, M. Cavassini, M. Stoeckle, E. Bernasconi, P. Schmid, A. Calmy, D. Haerry, C.
835 Beguelin, C.A. Fux, G. Wandeler, B. Surial, and A. Rauch. 2024. Long-term trends in hepatitis C
836 prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study. *Liver Int*
837 44:169-179.
838 Bayat, A., P.D. Burbelo, S.K. Browne, M. Quinlivan, B. Martinez, S.M. Holland, A. Buvanendran, J.S.
839 Kroin, A.J. Mannes, J. Breuer, J.I. Cohen, and M.J. Iadarola. 2015. Anti-cytokine autoantibodies in
840 postherpetic neuralgia. *J Transl Med* 13:333.
841 Bell, J.B., R. Barfoot, T. Iveson, R.L. Powles, and B.C. Millar. 1994. Neutralising antibodies in patients with
842 multiple myeloma receiving maintenance therapy with interferon alpha 2b. *Br J Cancer* 70:646-651.
843 Bodansky, A., S.E. Vazquez, J. Chou, T. Novak, A. Al-Musa, C. Young, M. Newhams, S. Kucukak, L.D.
844 Zambrano, A. Mitchell, C.Y. Wang, K. Moffitt, N.B. Halasa, L.L. Loftis, S.P. Schwartz, T.C. Walker,
845 E.H. Mack, J.C. Fitzgerald, S.J. Gertz, C.M. Rowan, K. Irby, R.C. Sanders, Jr., M. Kong, J.E.
846 Schuster, M.A. Staat, M.S. Zinter, N.Z. Cvijanovich, K.M. Tarquinio, B.M. Coates, H.R. Flori, M.K.
847 Dahmer, H. Crandall, M.L. Cullimore, E.R. Levy, B. Chatani, R. Nofziger, C.-N.S.G.I. Overcoming,
848 R.S. Geha, J. DeRisi, A.P. Campbell, M. Anderson, and A.G. Randolph. 2022. NFKB2
849 haploinsufficiency identified via screening for IFNalpha2 autoantibodies in children and adolescents
850 hospitalized with SARS-CoV-2-related complications. *J Allergy Clin Immunol*
851
852 Burbelo, P.D., S. Browne, S.M. Holland, M.J. Iadarola, and I. Alevizos. 2019. Clinical features of Sjogren's
853 syndrome patients with autoantibodies against interferons. *Clin Transl Med* 8:1.
854 Burbelo, P.D., S.K. Browne, E.P. Sampaio, G. Giaccone, R. Zaman, E. Kristosturyan, A. Rajan, L. Ding,
855 K.H. Ching, A. Berman, J.B. Oliveira, A.P. Hsu, C.M. Klimavicz, M.J. Iadarola, and S.M. Holland.
856 2010. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic
857 neoplasia. *Blood* 116:4848-4858.
858 Busnadiego, I., I.A. Abela, P.M. Frey, D.A. Hofmaenner, T.C. Scheier, R.A. Schuepbach, P.K. Buehler,
859 S.D. Brugger, and B.G. Hale. 2022. Critically ill COVID-19 patients with neutralizing autoantibodies
860 against type I interferons have increased risk of herpesvirus disease. *PLoS Biol* 20:e3001709.
861 Chang, S.E., A. Feng, W. Meng, S.A. Apostolidis, E. Mack, M. Artandi, L. Barman, K. Bennett, S.
862 Chakraborty, I. Chang, P. Cheung, S. Chinthrajah, S. Dhingra, E. Do, A. Finck, A. Gaano, R.
863 Gessner, H.M. Giannini, J. Gonzalez, S. Greib, M. Gundisch, A.R. Hsu, A. Kuo, M. Manohar, R.
864 Mao, I. Neeli, A. Neubauer, O. Oniyide, A.E. Powell, R. Puri, H. Renz, J. Schapiro, P.A.
865 Weidenbacher, R. Wittman, N. Ahuja, H.R. Chung, P. Jagannathan, J.A. James, P.S. Kim, N.J.
866 Meyer, K.C. Nadeau, M. Radic, W.H. Robinson, U. Singh, T.T. Wang, E.J. Wherry, C. Skevaki, E.T.
867 Luning Prak, and P.J. Utz. 2021. New-onset IgG autoantibodies in hospitalized patients with
868 COVID-19. *Nat Commun* 12:5417.
869 Chauvineau-Grenier, A., P. Bastard, A. Servajean, A. Gervais, J. Rosain, E. Jouanguy, A. Cobat, J.L.
870 Casanova, and B. Rossi. 2022. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19
871 Deaths in a French Hospital. *Journal of clinical immunology* 42:459-470.
872 Credle, J.J., J. Gunn, P. Sangkhaapreecha, D.R. Monaco, X.A. Zheng, H.J. Tsai, A. Wilbon, W.R.
873 Morgenlander, A. Rastegar, Y. Dong, S. Jayaraman, L. Tosi, B. Parekkadan, A.N. Baer, M.
874 Roederer, E.M. Bloch, A.A.R. Tobian, I. Zyskind, J.I. Silverberg, A.Z. Rosenberg, A.L. Cox, T. Lloyd,
875 A.L. Mammen, and H. Benjamin Larman. 2022. Unbiased discovery of autoantibodies associated

- 874 with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. *Nat*
875 *Biomed Eng* 6:992-1003.
- 876 Duncan, C.J.A., R.E. Randall, and S. Hambleton. 2021. Genetic Lesions of Type I Interferon Signalling in
877 Human Antiviral Immunity. *Trends Genet* 37:46-58.
- 878 Dunning, J., S. Blankley, L.T. Hoang, M. Cox, C.M. Graham, P.L. James, C.I. Bloom, D. Chaussabel, J.
879 Banchereau, S.J. Brett, M.F. Moffatt, A. O'Garra, P.J.M. Openshaw, and M. Investigators. 2018.
880 Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-
881 associated patterns in severe influenza. *Nat Immunol* 19:625-635.
- 882 EASL, E.A.f.t.S.o.t.L. 2023. EASL Clinical Practice Guidelines on hepatitis delta virus. *J Hepatol* 79:433-
883 460.
- 884 Eto, S., Y. Nukui, M. Tsumura, Y. Nakagama, K. Kashimada, Y. Mizoguchi, T. Utsumi, M. Taniguchi, F.
885 Sakura, K. Noma, Y. Yoshida, S. Ohshimo, S. Nagashima, K. Okamoto, A. Endo, K. Imai, H.
886 Kanegane, H. Ohnishi, S. Hirata, E. Sugiyama, N. Shime, M. Ito, H. Ohge, Y. Kido, P. Bastard, J.L.
887 Casanova, O. Ohara, J. Tanaka, T. Morio, and S. Okada. 2022. Neutralizing Type I Interferon
888 Autoantibodies in Japanese Patients with Severe COVID-19. *Journal of clinical immunology*
889 42:1360-1370.
- 890 Frasca, F., M. Scordio, L. Santinelli, L. Gabriele, O. Gandini, A. Criniti, A. Pierangeli, A. Angeloni, C.M.
891 Mastroianni, G. d'Ettorre, R.P. Viscidi, G. Antonelli, and C. Scagnolari. 2022. Anti-IFN-alpha/-omega
892 neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and
893 laboratory biomarkers of disease severity. *Eur J Immunol* 52:1120-1128.
- 894 Gervais, A., F. Rovida, M.A. Avanzini, S. Croce, A. Marchal, S.C. Lin, A. Ferrari, C.W. Thorball, O.
895 Constant, T. Le Voyer, Q. Philippot, J. Rosain, M. Angelini, M. Perez Lorenzo, L. Bizien, C. Achille,
896 F. Trespidi, E. Burdino, I. Cassaniti, D. Lilleri, C. Fornara, J.C. Sammartino, D. Cereda, C. Marrocu,
897 A. Piralla, C. Valsecchi, S. Ricagno, P. Cogo, O. Neth, I. Marin-Cruz, M. Pacenti, A. Sinigaglia, M.
898 Trevisan, A. Volpe, A. Marzollo, F. Conti, T. Lazzarotto, A. Pession, P. Viale, J. Fellay, S.
899 Ghirardello, M. Aubart, V. Ghisetti, A. Aiuti, E. Jouanguy, P. Bastard, E. Percivalle, F. Baldanti, A.
900 Puel, M.R. MacDonald, C.M. Rice, G. Rossini, K.O. Murray, Y. Simonin, A. Nagy, L. Barzon, L.
901 Abel, M.S. Diamond, A. Cobat, S.Y. Zhang, J.L. Casanova, and A. Borghesi. 2023. Autoantibodies
902 neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. *The*
903 *Journal of experimental medicine* 220:
- 904 Goncalves, D., M. Mezidi, P. Bastard, M. Perret, K. Saker, N. Fabien, R. Pescarmona, C. Lombard, T.
905 Walzer, J.L. Casanova, A. Belot, J.C. Richard, and S. Trouillet-Assant. 2021. Antibodies against
906 type I interferon: detection and association with severe clinical outcome in COVID-19 patients. *Clin*
907 *Transl Immunology* 10:e1327.
- 908 Gueler, A., A. Moser, A. Calmy, H.F. Gunthard, E. Bernasconi, H. Furrer, C.A. Fux, M. Battegay, M.
909 Cavassini, P. Vernazza, M. Zwahlen, M. Egger, and S.N.C. Swiss Hiv Cohort Study. 2017. Life
910 expectancy in HIV-positive persons in Switzerland: matched comparison with general population.
911 *AIDS* 31:427-436.
- 912 Gupta, S., I.P. Tatouli, L.B. Rosen, S. Hasni, I. Alevizos, Z.G. Manna, J. Rivera, C. Jiang, R.M. Siegel,
913 S.M. Holland, H.M. Moutsopoulos, and S.K. Browne. 2016. Distinct Functions of Autoantibodies
914 Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine
915 Autoantibodies in Common Rheumatic Diseases. *Arthritis Rheumatol* 68:1677-1687.
- 916 Hale, B.G. 2023. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and
917 association with viral disease susceptibility. *Eur J Immunol* 53:e2250164.
- 918 Hetemaki, I., S. Laakso, H. Valimaa, I. Kleino, E. Kekalainen, O. Makitie, and T.P. Arstila. 2021. Patients
919 with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe
920 herpesvirus infections. *Clin Immunol* 231:108851.
- 921 Höftberger, R., H. Lassmann, T. Berger, and M. Reindl. 2022. Pathogenic autoantibodies in multiple
922 sclerosis — from a simple idea to a complex concept. *Nature Reviews Neurology* 18:681-688.
- 923 Jorns, C., D. Holzinger, R. Thimme, H.C. Spangenberg, M. Weidmann, J. Rasenack, H.E. Blum, O. Haller,
924 and G. Kochs. 2006. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis
925 C non-responsive to IFN-alpha. *J Med Virol* 78:74-82.
- 926 Kisand, K., M. Link, A.S. Wolff, A. Meager, L. Tserel, T. Org, A. Murumagi, R. Uibo, N. Willcox, K.
927 Trebusak Podkrajsek, T. Battelino, A. Lobell, O. Kampe, K. Lima, A. Meloni, B. Ergun-Longmire,
928 N.K. Maclaren, J. Perheentupa, K.J. Krohn, H.S. Scott, E.S. Husebye, and P. Peterson. 2008.
929 Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-
930 stimulated genes. *Blood* 112:2657-2666.

- 931 Koning, R., P. Bastard, J.L. Casanova, M.C. Brouwer, D. van de Beek, and U.M.C.C.-B.I. with the
932 Amsterdam. 2021. Autoantibodies against type I interferons are associated with multi-organ failure
933 in COVID-19 patients. *Intensive care medicine* 47:704-706.
- 934 Le Voyer, T., A.V. Parent, X. Liu, A. Cederholm, A. Gervais, J. Rosain, T. Nguyen, M. Perez Lorenzo, E.
935 Rackaityte, D. Rinchai, P. Zhang, L. Bizien, G. Hancioglu, P. Ghillani-Dalbin, J.L. Charuel, Q.
936 Philippot, M.S. Gueye, M.R.L. Maglorius Renkilaraj, M. Ogishi, C. Soudee, M. Migaud, F.
937 Rozenberg, M. Momenilandi, Q. Riller, L. Imberti, O.M. Delmonte, G. Muller, B. Keller, J. Orrego,
938 W.A. Franco Gallego, T. Rubin, M. Emiroglu, N. Parvaneh, D. Eriksson, M. Aranda-Guillen, D.I.
939 Berrios, L. Vong, C.H. Katelaris, P. Mustillo, J. Raedler, J. Bohlen, J. Bengi Celik, C. Astudillo, S.
940 Winter, N.F.-k. Consortium, C.H.G. Effort, C. McLean, A. Guffroy, J.L. DeRisi, D. Yu, C. Miller, Y.
941 Feng, A. Guichard, V. Beziat, J. Bustamante, Q. Pan-Hammarstrom, Y. Zhang, L.B. Rosen, S.M.
942 Holland, M. Bosticardo, H. Kenney, R. Castagnoli, C.A. Slade, K. Boztug, N. Mahlaoui, S. Latour,
943 R.S. Abraham, V. Lougaris, F. Hauck, A. Sediva, F. Atschekzei, G. Sogkas, M.C. Poli, M.A. Slatter,
944 B. Palterer, M.D. Keller, A. Pinzon-Charry, A. Sullivan, L. Droney, D. Suan, M. Wong, A. Kane, H.
945 Hu, C. Ma, H. Grombirikova, P. Ciznar, I. Dalal, N. Aladjidi, M. Hie, E. Lazaro, J. Franco, S. Keles,
946 M. Malphettes, M. Pasquet, M.E. Maccari, A. Meinhardt, A. Ikinciogullari, M. Shahrooei, F. Celmeli,
947 P. Frosk, C.C. Goodnow, P.E. Gray, A. Belot, H.S. Kuehn, S.D. Rosenzweig, M. Miyara, F.
948 Licciardi, A. Servettaz, V. Barlogis, G. Le Guenno, V.M. Herrmann, T. Kuijpers, G. Ducoux, F.
949 Sarrot-Reynaud, C. Schuetz, C. Cunningham-Rundles, F. Rieux-Laucat, S.G. Tangye, C.
950 Sobacchi, R. Doffinger, K. Warnatz, B. Grimbacher, C. Fieschi, L. Berteloot, V.L. Bryant, S. Trouillet
951 Assant, H. Su, B. Neven, L. Abel, Q. Zhang, B. Boisson, A. Cobat, E. Jouanguy, O. Kampe, P.
952 Bastard, C.M. Roifman, N. Landegren, L.D. Notarangelo, M.S. Anderson, J.L. Casanova, and A.
953 Puel. 2023. Autoantibodies against type I IFNs in humans with alternative NF-kappaB pathway
954 deficiency. *Nature* 623:803-813.
- 955 Liang, Z., X. Dong, Z. Zhang, Q. Zhang, and Y. Zhao. 2022. Age-related thymic involution: Mechanisms
956 and functional impact. *Aging Cell* 21:e13671.
- 957 Liechti, T., C. Kadelka, H. Ebner, N. Friedrich, R.D. Kouyos, H.F. Günthard, and A. Trkola. 2018.
958 Development of a high-throughput bead based assay system to measure HIV-1 specific immune
959 signatures in clinical samples. *Journal of immunological methods* 454:48-58.
- 960 Lin, S.C., F.R. Zhao, H. Janova, A. Gervais, S. Rucknagel, K.O. Murray, J.L. Casanova, and M.S.
961 Diamond. 2023. Blockade of interferon signaling decreases gut barrier integrity and promotes
962 severe West Nile virus disease. *Nat Commun* 14:5973.
- 963 Lopez, J., M. Mommert, W. Mouton, A. Pizzorno, K. Brengel-Pesce, M. Mezidi, M. Villard, B. Lina, J.C.
964 Richard, J.B. Fassier, V. Cheynet, B. Padey, V. Duliere, T. Julien, S. Paul, P. Bastard, A. Belot, A.
965 Bal, J.L. Casanova, M. Rosa-Calatrava, F. Morfin, T. Walzer, and S. Trouillet-Assant. 2021. Early
966 nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies
967 against type I IFNs. *The Journal of experimental medicine* 218:
- 968 Manry, J., P. Bastard, A. Gervais, T. Le Voyer, J. Rosain, Q. Philippot, E. Michailidis, H.H. Hoffmann, S.
969 Eto, M. Garcia-Prat, L. Bizien, A. Parra-Martinez, R. Yang, L. Haljasmagi, M. Migaud, K.
970 Sarekannu, J. Maslovskaja, N. de Prost, Y. Tandjaoui-Lambiotte, C.E. Luyt, B. Amador-Borrero, A.
971 Gaudet, J. Poissy, P. Morel, P. Richard, F. Cognasse, J. Troya, S. Trouillet-Assant, A. Belot, K.
972 Saker, P. Garcon, J.G. Riviere, J.C. Lagier, S. Gentile, L.B. Rosen, E. Shaw, T. Morio, J. Tanaka,
973 D. Dalmau, P.L. Tharaux, D. Sene, A. Stepanian, B. Megarbane, V. Triantafyllia, A. Fekkar, J.R.
974 Heath, J.L. Franco, J.M. Anaya, J. Sole-Violan, L. Imberti, A. Biondi, P. Bonfanti, R. Castagnoli,
975 O.M. Delmonte, Y. Zhang, A.L. Snow, S.M. Holland, C.M. Biggs, M. Moncada-Velez, A.A. Arias, L.
976 Lorenzo, S. Boucherit, D. Anglicheau, A.M. Planas, F. Haerynck, S. Duvlis, T. Ozcelik, S. Keles,
977 A.A. Bousfiha, J. El Bakkouri, C. Ramirez-Santana, S. Paul, Q. Pan-Hammarstrom, L.
978 Hammarstrom, A. Dupont, A. Kurolap, C.N. Metz, A. Aiuti, G. Casari, V. Lampasona, F. Ciceri, L.A.
979 Barreiros, E. Dominguez-Garrido, M. Vidigal, M. Zatz, D. van de Beek, S. Sahanic, I. Tancevski, Y.
980 Stepanovskyy, O. Boyarchuk, Y. Nukui, M. Tsumura, L. Vidaur, S.G. Tangye, S. Burrell, D. Duffy, L.
981 Quintana-Murci, A. Klocperk, N.Y. Kann, A. Shcherbina, Y.L. Lau, D. Leung, M. Coulangeat, J.
982 Marlet, R. Koning, L.F. Reyes, A. Chauvineau-Grenier, F. Venet, G. Monneret, M.C. Nussenzweig,
983 R. Arrestier, I. Boudhabhay, H. Baris-Feldman, D. Hagin, J. Wauters, I. Meyts, A.H. Dyer, S.P.
984 Kennelly, N.M. Bourke, R. Halwani, F.S. Sharif-Askari, K. Dorgham, J. Sallette, S.M. Sedkaoui, S.
985 AlKhater, R. Rigo-Bonnin, F. Morandera, L. Roussel, D.C. Vinh, C. Erikstrup, A. Condino-Neto, C.
986 Prando, A. Bondarenko, A.N. Spaan, L. Gilardin, J. Fellay, S. Lyonnet, K. Bilguvar, R.P. Lifton, S.
987 Mane, H. Lab, C. Clinicians, C.-S. Clinicians, N.I.R.t.C. Group, N.-C.S. Group, C. Danish, S. Danish

- 988 Blood Donor, S.C.I.G. St. James's Hospital, C.C.S.G. French, C.-G. Imagine, C. Milieu Interieur,
989 V.C.C. Co, U.M.C.C.-B.I. Amsterdam, C.H.G. Effort, C.-C.-. Group, C. cohort, C.D. Study, H.-C.
990 Cerba, g. Etablissement Francais du Sang Study, M.S. Anderson, B. Boisson, V. Beziat, S.Y.
991 Zhang, E. Andreakos, O. Hermine, A. Pujol, P. Peterson, T.H. Mogensen, L. Rowen, J. Mond, S.
992 Debette, X. de Lamballerie, C. Burdet, L. Bouadma, M. Zins, P. Soler-Palacin, R. Colobran, G.
993 Gorochov, X. Solanich, S. Susen, J. Martinez-Picado, D. Raoult, M. Vasse, P.K. Gregersen, L.
994 Piemonti, C. Rodriguez-Gallego, L.D. Notarangelo, H.C. Su, K. Kisand, S. Okada, A. Puel, E.
995 Jouanguy, C.M. Rice, P. Tiberghien, Q. Zhang, J.L. Casanova, L. Abel, and A. Cobat. 2022. The
996 risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. *Proc*
997 *Natl Acad Sci U S A* 119:e2200413119.
- 998 Mathian, A., P. Breillat, K. Dorgham, P. Bastard, C. Charre, R. Lhote, P. Quentric, Q. Moyon, A.A.
999 Mariaggi, S. Mouries-Martin, C. Mellot, F. Anna, J. Haroche, F. Cohen-Aubart, D. Sterlin, N. Zahr,
1000 A. Gervais, T. Le Voyer, L. Bizien, Q. Amiot, M. Pha, M. Hie, F. Chasset, H. Yssel, M. Miyara, P.
1001 Charneau, P. Ghillani-Dalbin, J.L. Casanova, F. Rozenberg, Z. Amoura, and G. Gorochov. 2022.
1002 Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with
1003 systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. *Ann Rheum*
1004 *Dis* 81:1695-1703.
- 1005 Meager, A., K. Visvalingam, P. Peterson, K. Moll, A. Murumagi, K. Krohn, P. Eskelin, J. Perheentupa, E.
1006 Husebye, Y. Kadota, and N. Willcox. 2006. Anti-interferon autoantibodies in autoimmune
1007 polyendocrinopathy syndrome type 1. *PLoS Med* 3:e289.
- 1008 Meyer, S., M. Woodward, C. Hertel, P. Vlaicu, Y. Haque, J. Karner, A. Macagno, S.C. Onuoha, D.
1009 Fishman, H. Peterson, K. Metskula, R. Uibo, K. Jantti, K. Hokynar, A.S.B. Wolff, A.p. collaborative,
1010 K. Krohn, A. Ranki, P. Peterson, K. Kisand, and A. Hayday. 2016. AIRE-Deficient Patients Harbor
1011 Unique High-Affinity Disease-Ameliorating Autoantibodies. *Cell* 166:582-595.
- 1012 Meyts, I., and J.L. Casanova. 2021. Viral infections in humans and mice with genetic deficiencies of the
1013 type I IFN response pathway. *Eur J Immunol* 51:1039-1061.
- 1014 Mitchell, W.A., P.O. Lang, and R. Aspinall. 2010. Tracing thymic output in older individuals. *Clin Exp*
1015 *Immunol* 161:497-503.
- 1016 Mogensen, K.E., P. Daubas, I. Gresser, D. Sereni, and B. Varet. 1981. Patient with circulating antibodies
1017 to alpha-interferon. *Lancet* 2:1227-1228.
- 1018 Pozzetto, B., K.E. Mogensen, M.G. Tovey, and I. Gresser. 1984. Characteristics of autoantibodies to
1019 human interferon in a patient with varicella-zoster disease. *J Infect Dis* 150:707-713.
- 1020 Ramakrishnan, K.A., W. Rae, G. Barcenas-Morales, Y. Gao, R.J. Pengelly, S.V. Patel, D.S. Kumararatne,
1021 S. Ennis, R. Doffinger, S.N. Faust, and A.P. Williams. 2018. Anticytokine autoantibodies in a patient
1022 with a heterozygous NFKB2 mutation. *J Allergy Clin Immunol* 141:1479-1482 e1476.
- 1023 Ronnblom, L.E., E.T. Janson, A. Perers, K.E. Oberg, and G.V. Alm. 1992. Characterization of anti-
1024 interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. *Clin Exp*
1025 *Immunol* 89:330-335.
- 1026 Roszkiewicz, J., and E. Smolewska. 2016. Kaleidoscope of autoimmune diseases in HIV infection.
1027 *Rheumatol Int* 36:1481-1491.
- 1028 Scherrer, A.U., A. Traytel, D.L. Braun, A. Calmy, M. Battegay, M. Cavassini, H. Furrer, P. Schmid, E.
1029 Bernasconi, M. Stoeckle, C. Kahlert, A. Trkola, R.D. Kouyos, P. Tarr, C. Marzolini, G. Wandeler, J.
1030 Fellay, H. Bucher, S. Yerly, F. Suter, H. Hirsch, M. Huber, G. Dollenmaier, M. Perreau, G. Martinetti,
1031 A. Rauch, H.F. Gunthard, and H.I.V.C.S. Swiss. 2022. Cohort Profile Update: The Swiss HIV Cohort
1032 Study (SHCS). *Int J Epidemiol* 51:33-34j.
- 1033 Scordio, M., F. Frasca, L. Santinelli, L. Sorrentino, A. Pierangeli, O. Turriziani, C.M. Mastroianni, G.
1034 Antonelli, R.P. Viscidi, G. d'Ettore, and C. Scagnolari. 2022. High frequency of neutralizing
1035 antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. *Clin Immunol*
1036 241:109068.
- 1037 Sjogren, T., E. Bratland, E.C. Royrvik, M.A. Grytaas, A. Benneche, P.M. Knappskog, O. Kampe, B.E.
1038 Oftedal, E.S. Husebye, and A.S.B. Wolff. 2022. Screening patients with autoimmune endocrine
1039 disorders for cytokine autoantibodies reveals monogenic immune deficiencies. *J Autoimmun*
1040 133:102917.
- 1041 Solanich, X., R. Rigo-Bonnin, V.D. Gumucio, P. Bastard, J. Rosain, Q. Philippot, X.L. Perez-Fernandez,
1042 M.P. Fuset-Cabanes, M.A. Gordillo-Benitez, G. Suarez-Cuartin, E. Boza-Hernandez, A. Riera-
1043 Mestre, A. Parra-Martinez, R. Colobran, A. Antoli, S. Navarro, G. Rocamora-Blanch, M. Framil, L.
1044 Calatayud, X. Corbella, J.L. Casanova, F. Morandeira, and J. Sabater-Riera. 2021. Pre-existing

- 1045 Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19
1046 Patients Admitted to Intensive Care in Barcelona. *Journal of clinical immunology* 41:1733-1744.
- 1047 Steels, S., J. Van Elslande, C.-S.G. Leuven, P. De Munter, and X. Bossuyt. 2022. Transient Increase of
1048 Pre-existing Anti-IFN-alpha2 Antibodies Induced by SARS-CoV-2 Infection. *Journal of clinical*
1049 *immunology* 42:742-745.
- 1050 Stertz, S., and B.G. Hale. 2021. Interferon system deficiencies exacerbating severe pandemic virus
1051 infections. *Trends Microbiol* 29:973-982.
- 1052 Sundqvist, E., T. Bergström, H. Daialhosein, M. Nyström, P. Sundström, J. Hillert, L. Alfredsson, I.
1053 Kockum, and T. Olsson. 2014. Cytomegalovirus seropositivity is negatively associated with multiple
1054 sclerosis. *Multiple Sclerosis Journal* 20:165-173.
- 1055 Troya, J., P. Bastard, L. Planas-Serra, P. Ryan, M. Ruiz, M. de Carranza, J. Torres, A. Martinez, L. Abel,
1056 J.L. Casanova, and A. Pujol. 2021. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients
1057 with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain. *Journal of clinical immunology*
1058 41:914-922.
- 1059 Trutschel, D., P. Bost, X. Mariette, V. Bondet, A. Llibre, C. Posseme, B. Charbit, C.W. Thorball, R.
1060 Jonsson, C.J. Lessard, R. Felten, W.F. Ng, L. Chatenoud, H. Dumortier, J. Sibilia, J. Fellay, K.A.
1061 Brokstad, S. Appel, J.R. Tarn, L. Quintana-Murci, M. Mingueneau, N. Meyer, D. Duffy, B.
1062 Schwikowski, J.E. Gottenberg, A.s.i. Milieu Interieur Consortium, and N. Consortium. 2022.
1063 Variability of Primary Sjogren's Syndrome Is Driven by Interferon-alpha and Interferon-alpha Blood
1064 Levels Are Associated With the Class II HLA-DQ Locus. *Arthritis Rheumatol* 74:1991-2002.
- 1065 van der Wijst, M.G.P., S.E. Vazquez, G.C. Hartoularos, P. Bastard, T. Grant, R. Bueno, D.S. Lee, J.R.
1066 Greenland, Y. Sun, R. Perez, A. Ogorodnikov, A. Ward, S.A. Mann, K.L. Lynch, C. Yun, D.V. Havlir,
1067 G. Chamie, C. Marquez, B. Greenhouse, M.S. Lionakis, P.J. Norris, L.J. Dumont, K. Kelly, P.
1068 Zhang, Q. Zhang, A. Gervais, T. Le Voyer, A. Whatley, Y. Si, A. Byrne, A.J. Combes, A.A. Rao,
1069 Y.S. Song, G.K. Fragiadakis, K. Kangelaris, C.S. Calfee, D.J. Erle, C. Hendrickson, M.F. Krummel,
1070 P.G. Woodruff, C.R. Langelier, J.L. Casanova, J.L. Derisi, M.S. Anderson, C.J. Ye, and U.C.
1071 consortium. 2021. Type I interferon autoantibodies are associated with systemic immune alterations
1072 in patients with COVID-19. *Science translational medicine* 13:eabh2624.
- 1073 Vandoren, R., M. Boeren, J. Schippers, E. Bartholomeus, K. Mullan, N. Michels, O. Aerts, J. Leysen, A.
1074 Bervoets, J. Lambert, E. Leuridan, J. Wens, K. Peeters, M.P. Emonds, H. Jansens, J.L. Casanova,
1075 P. Bastard, A. Suls, V. Van Tendeloo, P. Ponsaerts, P. Delputte, B. Ogunjimi, K. Laukens, and P.
1076 Meysman. 2024. Unravelling the immune signature of herpes zoster: Insights into pathophysiology
1077 and the HLA risk profile. *J Infect Dis*
- 1078 Walter, J.E., L.B. Rosen, K. Csomos, J.M. Rosenberg, D. Mathew, M. Keszei, B. Ujhazi, K. Chen, Y.N.
1079 Lee, I. Tirosh, K. Dobbs, W. Al-Herz, M.J. Cowan, J. Puck, J.J. Bleesing, M.S. Grimley, H. Malech,
1080 S.S. De Ravin, A.R. Gennery, R.S. Abraham, A.Y. Joshi, T.G. Boyce, M.J. Butte, K.C. Nadeau, I.
1081 Balboni, K.E. Sullivan, J. Akhter, M. Adeli, R.A. El-Feky, D.H. El-Ghoneimy, G. Dbaibo, R. Wakim,
1082 C. Azzari, P. Palma, C. Cancrini, K. Capuder, A. Condino-Neto, B.T. Costa-Carvalho, J.B. Oliveira,
1083 C. Roifman, D. Buchbinder, A. Kumanovics, J.L. Franco, T. Niehues, C. Schuetz, T. Kuijpers, C.
1084 Yee, J. Chou, M.J. Masaad, R. Geha, G. Uzel, R. Gelman, S.M. Holland, M. Recher, P.J. Utz, S.K.
1085 Browne, and L.D. Notarangelo. 2015. Broad-spectrum antibodies against self-antigens and
1086 cytokines in RAG deficiency. *J Clin Invest* 125:4135-4148.
- 1087 Wang, E.Y., T. Mao, J. Klein, Y. Dai, J.D. Huck, J.R. Jaycox, F. Liu, T. Zhou, B. Israelow, P. Wong, A.
1088 Coppi, C. Lucas, J. Silva, J.E. Oh, E. Song, E.S. Perotti, N.S. Zheng, S. Fischer, M. Campbell, J.B.
1089 Fournier, A.L. Wyllie, C.B.F. Vogels, I.M. Ott, C.C. Kalinich, M.E. Petrone, A.E. Watkins, I.T. Yale,
1090 C. Dela Cruz, S.F. Farhadian, W.L. Schulz, S. Ma, N.D. Grubaugh, A.I. Ko, A. Iwasaki, and A.M.
1091 Ring. 2021. Diverse functional autoantibodies in patients with COVID-19. *Nature* 595:283-288.
- 1092 Waubant, E., E.M. Mowry, L. Krupp, T. Chitnis, E.A. Yeh, N. Kuntz, J. Ness, D. Chabas, J. Strober, J.
1093 McDonald, A. Belman, M. Milazzo, M. Gorman, B. Weinstock-Guttman, M. Rodriguez, J.R.
1094 Oksenberg, J.A. James, and U.S.P.M. Network. 2011. Common viruses associated with lower
1095 pediatric multiple sclerosis risk. *Neurology* 76:1989-1995.
- 1096 Zandman-Goddard, G., and Y. Shoenfeld. 2002. HIV and autoimmunity. *Autoimmun Rev* 1:329-337.
- 1097 Zhang, Q., A. Pizzorno, L. Miorin, P. Bastard, A. Gervais, T. Le Voyer, L. Bizien, J. Manry, J. Rosain, Q.
1098 Philippot, K. Goavec, B. Padey, A. Cupic, E. Laurent, K. Saker, M. Vanker, K. Sarekannu, C.H.G.
1099 Effort, G. Etablissement Francais du Sang Study, C. Constances, C.D. Study, G. Cerba
1100 HealthCare, G. Lyon Antigrippe Working, R.I.W. Group, T. Garcia-Salum, M. Ferres, N. Le Corre, J.
1101 Sanchez-Cespedes, M. Balsera-Manzanero, J. Carratala, P. Retamar-Gentil, G. Abelenda-Alonso,

1102 A. Valiente, P. Tiberghien, M. Zins, S. Debette, I. Meyts, F. Haerynck, R. Castagnoli, L.D.
1103 Notarangelo, L.I. Gonzalez-Granado, N. Dominguez-Pinilla, E. Andreakos, V. Triantafyllia, C.
1104 Rodriguez-Gallego, J. Sole-Violan, J.J. Ruiz-Hernandez, F. Rodriguez de Castro, J. Ferreres, M.
1105 Briones, J. Wauters, L. Vanderbeke, S. Feys, C.Y. Kuo, W.T. Lei, C.L. Ku, G. Tal, A. Etzioni, S.
1106 Hanna, T. Fournet, J.S. Casalegno, G. Queromes, L. Argaud, E. Javouhey, M. Rosa-Calatrava, E.
1107 Cordero, T. Aydillo, R.A. Medina, K. Kisan, A. Puel, E. Jouanguy, L. Abel, A. Cobat, S. Trouillet-
1108 Assant, A. Garcia-Sastre, and J.L. Casanova. 2022. Autoantibodies against type I IFNs in patients
1109 with critical influenza pneumonia. *J Exp Med* 219:

1110

1111

FIGURE LEGENDS

1112

1113 **Figure 1. Identification and characterization of anti-IFN-I autoAbs in an aging,**
1114 **longitudinally-sampled, infectious disease patient cohort. (A-C)** Validated screening results
1115 for presence of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG in plasma samples derived from 1876
1116 unique patients enrolled in the SHCS and aged >65 years at the time of sampling. Median
1117 Fluorescence Intensity (MFI) Fold Change (FC) of IgG values obtained from IFN-I-coated beads
1118 relative to the MFI of IgG values obtained from empty beads is shown, normalized to the cohort
1119 means for each IFN-I. All individual patient samples are shown (circles), with samples
1120 considered positive after subsequent analysis of longitudinal samples colored (see Methods for
1121 thresholds). Solid colored circles represent plasma samples that also neutralized the respective
1122 IFN-I in subsequent assays. Numbers and percentage of positive patients (neutralizing and non-
1123 neutralizing IgG) are indicated for each anti-IFN-I IgG. (B) Pairwise representation of the data
1124 shown in (A) comparing the indicated combinations of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG
1125 found in each patient plasma sample. (C) Venn diagram analysis of the 35 anti-IFN-I autoAb-
1126 positive patients highlighting the anti-IFN-I autoAb specificities observed for neutralizing and
1127 non-neutralizing IgG. Percentages refer to the entire sub-cohort (1876 patients). The asterisk
1128 denotes the inclusion of a single patient found to possess binding and neutralizing anti-IFN α 2
1129 IgG, as well as binding and non-neutralizing anti-IFN ω IgG. **(D-E)** Plasma samples from anti-
1130 IFN-I autoAb-positive patients were analyzed to determine relative levels (%) of each of the four
1131 IgG subclasses targeting IFN-I. (D) Patient-level analysis shown as a heat-map, where white

1132 blocks indicate no anti-IFN-I IgG subclass was detected, and slashed blocks indicate IgG
1133 subclass was not determined. (E) IgG subclass analysis in all patients for each IFN-I. Statistical
1134 analysis was performed using a one-way ANOVA with Tukey's multiple comparison (single
1135 pooled variance). *P* values and significance are indicated (ns = non-significant).

1136
1137 **Figure 2. High-resolution longitudinal analysis of anti-IFN-I autoAb development over**
1138 **decades.** Semiannually biobanked plasma samples available for all 35 anti-IFN-I autoAb-
1139 positive patients (and several negative patients) were analyzed for anti-IFN α 2, anti-IFN β and
1140 anti-IFN ω IgG levels, as well as for IFN α 2, IFN β or IFN ω neutralization capacity. **(A)** Frequency
1141 of ages (years) where each anti-IFN-I autoAb was first detected. The median age of first
1142 detection (induction) is noted. **(B)** MFI FC values for each anti-IFN α 2, anti-IFN β and anti-IFN ω
1143 IgG in each patient comparing relative levels between the first timepoint where anti-IFN-I
1144 autoAbs were detected and the last available timepoint sampled. Statistical analysis was
1145 performed using a Wilcoxon matched-pairs signed rank test. *P* values and significance are
1146 indicated (ns = non-significant). **(C-I)** Patient-level representation of anti-IFN α 2, anti-IFN β and
1147 anti-IFN ω IgG levels (MFI FC), as well as IFN α 2, IFN β or IFN ω neutralization (inhibition of IFN-
1148 induced Luciferase (Luc) activity) at 3 different doses (see Methods), for all available longitudinal
1149 samples plotted as a function of patient age (years). Colored circles represent samples
1150 considered positive for either binding IgG or neutralization (see Methods for thresholds).
1151 Triangles in neutralization plots represent negative controls. In (C-I), individual patients are
1152 grouped according to the types of IFN-I to which they possess binding and neutralizing IgG
1153 (indicated at the top of each panel, together with the n/35 patients who have a similar
1154 phenotype). The patient in (I) is a negative patient who never developed anti-IFN-I autoAbs. See
1155 also Supplementary Figures 1 and 2.

1156

1157 **Figure 3. Neutralizing anti-IFN α 2 autoAbs are associated with compromised baseline IFN-**
1158 **stimulated gene (ISG) levels. (A)** Area under the curve (AUC) values for clinically determined
1159 cell compositions in whole blood (as indicated) in 16 patients who developed neutralizing anti-
1160 IFN α 2 autoAbs. Existing clinical cell titers were obtained for each patient from the SHCS, and
1161 AUC values were determined from all available data up to 1 year before (Pre) or 1 year after
1162 (Post) the timepoint where anti-IFN α 2 autoAbs were first detected. Statistical analysis was
1163 performed using a paired Wilcoxon signed rank test. *P* values are indicated. **(B-C)** RT-qPCR
1164 analysis of the indicated ISGs in PBMCs from 13 patients who developed neutralizing anti-IFN α
1165 autoAbs (B) or 13 age-matched control patients who never developed anti-IFN-I autoAbs (C).
1166 Data shown for each patient represent mean percentage changes in expression of the indicated
1167 ISG relative to the first timepoint (i.e. samples taken before development of anti-IFN α autoAbs
1168 for (B), or to the equivalent timepoint for (C)). Statistical significance of changes across the 13
1169 patients was determined based on the original Δ Ct values (normalized to *GAPDH*) using a
1170 Mann-Whitney U test. *P* values and significance are indicated (ns = non-significant).

1171
1172 **Figure 4. Prior infections and immune factors influence the development of anti-IFN-I**
1173 **autoAbs. (A-C)** Mosaic plots comparing the SHCS recorded incidence of prior CMV positivity
1174 (A), prior herpes zoster diagnosis (B), or prior ANA test positivity (C) between patients who
1175 developed anti-IFN-I autoAbs and matched control patients who did not. In (A) and (B), only
1176 patients with complete data for the indicated parameter were included (therefore n differs slightly
1177 with that in Supplementary Table 3). In (C), only patients who were tested are included. **(D)**
1178 Screening results for the presence of 19 different anti-autoantigen IgGs in plasma samples
1179 derived from 22 anti-IFN-I autoAb positive (Pos) patients and 22 age-matched negative control
1180 (Neg) patients who were confirmed to have never developed anti-IFN-I autoAbs. Two samples
1181 per patient were tested, which were the two samples immediately preceding first detection of
1182 anti-IFN-I autoAbs (for the positive patients; typically 6 and 12 months before) or age-matched

1183 timepoints for the negative patients. MFI FC IgG values obtained from the indicated autoantigen-
1184 coated beads are shown relative to the MFI of IgG values obtained from empty beads
1185 normalized to the negative patient mean for each autoantigen. All patient samples are shown
1186 (circles). Patient plasmas exhibiting normalized MFI values >5 SDs above the mean MFIs
1187 obtained from the negative patient samples (dotted lines) were considered positive for the
1188 specific anti-autoantigen IgG and are colored and labelled. **(E)** Mosaic plot analysis of the data in
1189 (D). For panels (A) and (B) statistical analyses were performed using conditional-logistic
1190 regression (taking into account the matched nature of the data) and likelihood-ratio tests, for
1191 panel (C) statistical analysis was performed using Fisher's Exact Test for Count Data (as the
1192 routine ANA data were not available for matched pairs of cases and controls), and for panel (E)
1193 statistical analysis was performed using Exact McNemar test (as this takes into account both the
1194 paired nature of the data and the absence of events in one group). *P* values are indicated.

1195
1196 **Figure 5. Therapeutic IFN α likely triggered development and lifelong persistence of**
1197 **neutralizing anti-IFN α autoAbs in an individual with pre-existing autoimmunity. (A)**
1198 Representation of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels (MFI FC), as well as IFN α 2
1199 neutralization (inhibition of IFN-induced Luciferase (Luc) activity) at 3 different doses (see
1200 Methods), for all available longitudinal samples from patient P7 (who was treated therapeutically
1201 with IFN α 2) plotted as a function of patient age (years). **(B)** Validated screening results for the
1202 presence of anti-IFN α 2 IgG in plasma samples derived from 300 unique patients enrolled in the
1203 SHCS who were treated with IFN α 2. Two samples per patient were assayed: the first sample
1204 available after IFN α treatment (typically around 6 months), and the last sample available (most
1205 recent: typically 10-20 years later). MFI FC values obtained from IFN α 2-coated beads relative to
1206 the MFI of values obtained from empty beads is shown, normalized to the cohort mean. All
1207 individual patient samples are shown (circles), with samples considered positive after
1208 subsequent analysis of longitudinal samples colored (see Methods for thresholds). Solid colored

1209 circles represent plasma samples that also neutralized IFN α when assayed. Positive patient
1210 samples are labeled. **(C-E)** Representation of data similar to (A), but for all available longitudinal
1211 samples from the indicated patients who had also been treated therapeutically with IFN α 2. **(F)**
1212 Heatmap representation of screening results for the presence of 19 different anti-autoantigen
1213 IgGs in plasma samples derived from 8 patients who had been treated therapeutically with
1214 IFN α 2. Two samples per patient were tested, which were the two samples immediately
1215 preceding the start of IFN α 2 treatment (typically 6 and 12 months before), as well as
1216 immediately preceding first detection of anti-IFN-I autoAbs (for newly-identified patient *P36).
1217 MFI FC IgG values obtained from the indicated autoantigen-coated beads are shown relative to
1218 the MFI of IgG values obtained from empty beads normalized to the means of controls shown in
1219 Fig. 4. Patient plasmas exhibiting normalized MFI values >5 SDs above the mean MFIs obtained
1220 from the controls shown in Fig. 4 were considered positive for the specific anti-autoantigen IgG
1221 and are colored. Note that the samples for P7 are the same as shown in Fig. 4 as the start of
1222 IFN α 2 treatment coincided with first detection of anti-IFN-I autoAbs. **(G)** Representation of anti-
1223 IFN α 2 (from panel A) and anti- β 2-GPI IgG levels (MFI FC), in selected longitudinal samples from
1224 patient P7 plotted as a function of patient age (years). In panels (A-E) and (G), colored circles
1225 represent samples considered positive for either binding IgG or neutralization (see Methods for
1226 thresholds). Triangles in neutralization plots represent negative controls. Blue shading indicates
1227 the period of time when each patient underwent IFN α 2 treatment.

1228
1229 **Supplementary Figure 1. High-resolution longitudinal analysis of anti-IFN-I autoAb**
1230 **development over decades (continued from Figure 2).** Semiannually biobanked plasma
1231 samples available for all 35 anti-IFN-I autoAb-positive patients were analyzed for anti-IFN α 2,
1232 anti-IFN β and anti-IFN ω IgG levels, as well as for IFN α 2, IFN β or IFN ω neutralization capacity.
1233 **(A-E)** Patient-level representation of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels (MFI FC),
1234 as well as IFN α 2, IFN β or IFN ω neutralization (inhibition of IFN-induced Luciferase (Luc) activity)

1235 at 3 different doses (see Methods), for all available longitudinal samples plotted as a function of
1236 patient age (years). Colored circles represent samples considered positive for either binding IgG
1237 or neutralization (see Methods for thresholds). Triangles in neutralization plots represent
1238 negative controls. In all panels, individual patients are grouped according to the types of IFN-I to
1239 which they possess binding and neutralizing IgG (indicated at the top of each panel, together
1240 with the n/35 patients who have a similar phenotype).

1241
1242 **Supplementary Figure 2. High-resolution longitudinal analysis of anti-IFN-I autoAbs over**
1243 **decades in negative patients (continued from Figure 2).** Semiannually biobanked plasma
1244 samples available for 5 patients who were negative for anti-IFN-I autoAbs in initial screenings
1245 were analyzed for anti-IFN α 2, anti-IFN β and anti-IFN ω IgG. Each panel is a patient-level
1246 representation of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels (MFI FC) plotted as a function
1247 of patient age (years). All samples were considered negative for binding IgG based on
1248 established thresholds (see Methods for details).









